1. Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R, et al. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol. 2018;179(4):G1-g46.
2. Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR, et al. Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(11):1476-90.
3. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, et al. Combination chemotherapy in advanced adrenocortical carcinoma. N Engl J Med. 2012;366(23):2189-97.
4. Mete O, Erickson LA, Juhlin CC, de Krijger RR, Sasano H, Volante M, et al. Overview of the 2022 WHO Classification of Adrenal Cortical Tumors. Endocr Pathol. 2022;33(1):155-96.
5. Giordano TJ. The Argument for Mitotic Rate-based Grading for the Prognostication of Adrenocortical Carcinoma. The American Journal of Surgical Pathology. 2011;35(4):471-3.
6. Giordano TJ, Berney D, de Krijger RR, Erickson L, Fassnacht M, Mete O, et al. Data set for reporting of carcinoma of the adrenal cortex: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting. Hum Pathol. 2021;110:50-61.
7. Hendricks A, Müller S, Fassnacht M, Germer CT, Wiegering VA, Wiegering A, et al. Impact of Lymphadenectomy on the Oncologic Outcome of Patients with Adrenocortical Carcinoma- A Systematic Review and Meta-Analysis. Cancers (Basel). 2022; 7;14(2):291. https://doi.org/10.3390/cancers14020291.
8. Kimpel O, Bedrose S, Megerle F, Berruti A, Terzolo M, Kroiss M, et al. Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study. Br J Cancer. 2021;125(9):1233-8.
9. Roux C, Boileve A, Faron M, Lamartina L, Delpla A, Tselikas L, et al. Loco-Regional Therapies in Oligometastatic Adrenocortical Carcinoma. Cancers (Basel). 2022;14(11) , 2730; https://doi.org/10.3390/cancers14112730.
10. Landwehr LS, Altieri B, Schreiner J, Sbiera I, Weigand I, Kroiss M, et al. Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinoma. J Immunother Cancer. 2020;8(1) :e000469. https://doi.org/10.1136/jitc-2019-000469.
11. Baechle JJ, Hanna DN, Sekhar KR, Rathmell JC, Rathmell WK, Baregamian N. Integrative computational immunogenomic profiling of cortisol-secreting adrenocortical carcinoma. J Cell Mol Med. 2021;25(21):10061-72.
12. Mete O, Asa SL, Gill AJ, Kimura N, de Krijger RR, Tischler A. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 2022;33(1):90- 114.
13. Nölting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, Kroiss M, et al. Personalized Management of Pheochromocytoma and Paraganglioma. Endocrine Reviews. 2021;43(2):199-239.
14. Hadoux J, Favier J, Scoazec J-Y, Leboulleux S, Al Ghuzlan A, Caramella C, et al. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma. International Journal of Cancer. 2014;135(11):2711- 20.
15. Perez K, Jacene H, Hornick JL, Ma C, Vaz N, Brais LK, et al. SDHx mutations and temozolomide in malignant pheochromocytoma and paraganglioma. Endocr Relat Cancer. 2022 19;29(9):533-544. https://doi.org/10.1530/ERC-21-0392.
16. Calissendorff J, Juhlin CC, Sundin A, Bancos I, Falhammar H. Adrenal myelolipomas. Lancet Diabetes Endocrinol. 2021;9(11):767-75.
17. Incampo G, Di Filippo L, Grossrubatscher EM, Dalino Ciaramella P, Frara S, Giustina A, et al. Adrenal schwannoma: why should endocrinologists be aware of this uncommon tumour? Endocrine. 2022;75(3):684-97.
18. Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26(1):1- 133.
19. Leboulleux S, Bournaud C, Chougnet CN, Zerdoud S, Al Ghuzlan A, Catargi B, et al. Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer. N Engl J Med. 2022;386(10):923-32.
20. Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, et al. BRAF Mutation s in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 2007;92(7):2840-3.
21. Ho AL, Dedecjus M, Wirth LJ, Tuttle RM, Inabnet WB, 3rd, Tennvall J, et al. Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA). J Clin Oncol. 2022;40(17):1870- 8.
22. Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015;372(7):621-30.
23. Brose MS, Robinson B, Sherman SI, Krajewska J, Lin CC, Vaisman F, et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double- blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2021;22(8):1126-38.
24. Elisei R, Schlumberger MJ, Müller SP, Schöffski P, Brose MS, Shah MH, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol. 2013;31(29):3639-46.
25. Koehler VF, Adam P, Frank-Raue K, Raue F, Berg E, Hoster E, et al. Real-World Efficacy and Safety of Cabozantinib and Vandetanib in Advanced Medullary Thyroid Cancer. Thyroid. 2021;31(3):459-69.
26. Koehler VF, Berg E, Adam P, Weber GL, Pfestroff A, Luster M, et al. Real-World Efficacy and Safety of Multi-Tyrosine Kinase Inhibitors in Radioiodine Refractory Thyroid Cancer. Thyroid. 2021;31(10):1531-41.
27. Wirth LJ, Sherman E, Robinson B, Solomon B, Kang H, Lorch J, et al. Efficacy of Selpercatinib in RET-Altered Thyroid Cancers. N Engl J Med. 2020;383(9):825-35.
28. Subbiah V, Hu MI, Wirth LJ, Schuler M, Mansfield AS, Curigliano G, et al. Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi- cohort, open-label, registrational, phase 1/2 study. Lancet Diabetes Endocrinol. 2021;9(8):491-501.
29. Lee YA, Lee H, Im SW, Song YS, Oh DY, Kang HJ, et al. NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake. J Clin Invest. 2021;131(18).
30. Groussin L, Bessiene L, Arrondeau J, Garinet S, Cochand-Priollet B, Lupo A, et al. Letter to the Editor: Selpercatinib-Enhanced Radioiodine Uptake in RET-Rearranged Thyroid Cancer. Thyroid. 2021;31(10):1603-4.
31. Dias-Santagata D, Lennerz JK, Sadow PM, Frazier RP, Govinda Raju S, Henry D, et al. Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma. Thyroid. 2020;30(9):1384-9.
32. Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study. Ann Oncol. 2022;33(4):406-15.
33. Subbiah V, Kreitman RJ, Wainberg ZA, Cho JY, Schellens JHM, Soria JC, et al. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600- Mutant Anaplastic Thyroid Cancer. J Clin Oncol. 2018;36(1):7-13.
34. Wirth LJ, Brose MS, Sherman EJ, Licitra L, Schlumberger M, Sherman SI, et al. Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer. J Clin Oncol. 2021;39(21):2359-66.
35. Dierks C, Seufert J, Aumann K, Ruf J, Klein C, Kiefer S, et al. Combination of Lenvatinib and Pembrolizumab Is an Effective Treatment Option for Anaplastic and Poorly Differentiated Thyroid Carcinoma. Thyroid. 2021;31(7):1076-85.

1. Araujo TF, Friedrich C, Grangeiro CHP, Martelli LR, Grzesiuk JD, Emich J, Wyrwoll MJ, Kliesch S, Simöes AL, Tüttelmann F. Sequence analysis of 37 candidate genes for male infertility: challenges in variant assessment and validating genes. Andrology 2020;8:434-441.
2. Aprea I, Raidt J, Höben IM, Loges NT, Nöthe-Menchen T, Pennekamp P, Olbricht H, Kaiser T, Biebach L, Tüttelmann F, Horvath J, Schubert M, Krallmann C, Kliesch S, Omran H. Defects in the cytoplasmic assembly of axonemal dynein arms cause mrophological abnormalities and dysmotility in sperm cells leading to male infertility. PLOS Genetics 2021; https://doi.org/10.1371/journal.pgen.1009306.
3. Barnouin Y, Armamento-Villareal R, Celli A, Jiang B, Paudyal A, Nambi V, Bryant MS, Marcelli M, Garcia JM, Qualls C, Villareal DT. Testosterone replacement therapy added to intensive lifestyle intervention in older men with obesity and hypogonadism. JCEM 2021; 106: e1096-e1110
4. Chu KY, Nacjeeran S, Horodyski L, Masterson TA, Ramasamy R. COVID-19 infectin is associated with new onset erectile dysfunction: insights from a nation registry. Sex Med 2022; 10:100478
5. Dubin JM, White J, Ory J, Ramasamy R. Vasectomy reversal vs. sperm retrieval with in vitro fertilitzation: a contemporary, comparative analysis. Fertil Steril 2021; 115: 1377- 1383
6. Houston BJ, Riera Escamilla R, Wyrwoll MJ, et al. A systematic review oft he validated monogenic causes of human male infertility: 2020 update and a discussion of emerging genedisease relationships. Hum Reprod Update 2021; 28: 15-29
7. Jayasena CN, Anderson RA, Llahana S, Barth JH, MacKenzie F, wilkes S, Smith N, Sooriakumaran P, Minhas S, Wu FCW, Tomlinson J, Quinton R. Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clin Endocrinol 2021; 96: 200-219
8. Kliesch S. “Praktisches Spermiogramm” – Ejakulatdiagnostik gemäß WHO. Urologe 2021; 60:647-656
9. Kliesch S, Schmidt S, Wilborn D, Aigner C, Albrecht W, Bedke J et al. Albers P. Management of germ cell tumors of the testis in adult patients. German Clinical Practice Guideline Part I: Epidemiology, classification, diagnosis, prognosis, fertility preservation, and treatment recommendations for localized stages. Urol Int 2021; 05: 69-180
10. Krenz H, Sansone A, Kliesch S, Gromoll J, Schubert M. FSHB genotype identified as a relevant diagnostic parameter revealed by cluster analysis of men with idiopathic infertility. Frontiers in Endocrinology, 2021, 12: https://doi.org/10.3389/fendo.2021.780403.
11. Krenz H, Sansone A, Fujarski M, Krallmann C, Zitzmann M, Dugas M, Kliesch S, Varghese J, Tüttelmann F, Gromoll J. Machine learning based prediction models in male reproductive health: Development of a proof-of-concept model for Klinefelter Syndrome in azoospermic patients. Andrology 2022; 10: 534-544
12. Kulkarni V, Kaingade P, Kulkarni N, Bhalerao T, Nikam A. Assessment of semen parameters in consecutive ejalculates with short abstinence period in oligospermic males. J Assisted Reprod 2022; 26:310-314.
13. Lotti F, Firzza F, Balerica G, Barbonetti A, Behre HM, Calogero AE, Cremers JF, Francavilla F, Isidori AM, Kliesch S, La Vignera S, Lenzi A, Marcou M, Pilatz A, Poolamets O, Punab M, Godoy MFP, Rajmil O, Salvio G, Schaeer O, Weidner W, Maseroli E, Cipriani S, Baldi E, Degl ́Ínnocenti S, Danza G, Caldini AL, Trreni A, Boni L, Krausz C, Maggi M. The European Academy of Andrology (EAA) ultrasound study on healthy , fertile men: scrotal ultrasound reference ranges and associations with clinical, seminal and biochemical chracteristics. Andrology 2021, 9:559-576
14. Lotti F, Firzza F, Balerica G, Barbonetti A, Behre HM, Calogero AE, Cremers JF, Francavilla F, Isidori AM, Kliesch S, La Vignera S, Lenzi A, Marcou M, Pilatz A, Poolamets O, Punab M, Godoy MFP, Quintian C, Rajmil O, Salvio G, Schaeer O, Weidner W, Maseroli E, Cipriani S, Baldi E, Degl ́Ínnocenti S, Danza G, Caldini AL, Terreni A, Boni L, Krausz C, Maggi M. The European Academy of Andrology (EAA) ultrasound study on healthy, fertile men: Prostate-vesicular transrectal ultrasound reference ranges and associations with clinical, seminal and biochemical characteristics. Andrology 2022, June 23 https://doi.org/10.1111/andr.13217 online ahead of print.
15. Maijoub A, Tadros NN, Polackwich AS, Aharma R, Agarwal A, Sabanehg E. Vasectomy reversal semen analysis: new reference ranges predict pregnancy. Fertil Steril 2017;107:911- 915
16. Meitei HY, Uppangala S, Lashmi RV, Guddattu V, Jegde P, Kumar P, Adiga P, Kalthur G, Schlatt S, Adiga SK. Sperm characteristics in normal and abnomal ejaculates are differently influenced by the length of ejaculatory abstinence. Andrology 2022; https://doi.org/10.1111/andr.13222.
17. Myers J, Prakash M, Froelicher V, Do D, Partington S, Atwood JE. Exercise capacity and mortality among men referred for exercise testing. N Engl J Med 2002;346:793-801
18. Oud MS, Volozonoka L, Smits RM, Vissers L, Ramos L, Veltman JA. A systematic review and standardized clinical validity assessment of male infertility genes. Hum Reprod 2019; 34: 932- 941
19. Oud MS, Volozonoka L, Friedrich C, Kliesch S, Nagimaja L, Gillssen C, O ́Bryan MK, MacLachlan RI, Aston KI, Tüttelmann F et al. Lack of evidence for a role of PIWIL1 variants in human male infertility. Cell 202; 84: 1941-1942
20. Salas-Huetos A, Tüttelmann F, Wyrwoll MJ, Kliesch S, Lopes AM, Concalves J, Boyden SE, Wöste M, Hotaling JM, GEMINI Consortium, Nagirnaja L, Conrad DF, Carrell DT, Aston KI. Disruption of human meiotic telomere complex genes TERB1, TERB2 and MAJIN in men with non-obstructive azoospermia. Hum Genet 2021a; 140:218-227
21. Salas-Huetos A, Tüttelmann F, Wyrwoll MJ, Kliesch S, Lopes AM, Concalves J, Boyden SE, Wöste M, Hotaling JM, GEMINI Consortium, Nagirnaja L, Conrad DF, Carrell DT, Aston KI. Correction to: Disruption of human meiotic telomere complex genes TERB1, TERB2 and MAJIN in men with non-obstructive azoospermia. Hum Genet 2021b; 140:Erratum
22. Salonia A, Bettocchi C, Carvalho J, Corona G, Jones TH, Kadioglu A, Martinez-Salamanca JI, Minhas S, Serefoglu EC, Verze P. European Guidelines on Sexual and Reproductive Male Health. European Association of Urology 2020. https://uroweb.org/wp-content/uploads/EAU-Guidelines-on-Sexual-and-Reproductive-Health-2020.pdf
23. Schistermann EF, Sjaarda LA, Clemons T, Carrell T, Perkins NJ, Johnstone E, Lamb D, Chaney K, Van Voorhis BJ, Ryan G, Summers K, Hotaling J, Robins J, Mills J, Mendola P, Chen Z, DeVilbiss EA, Peterson cm, Mumford SL. Effect of Folic Acid and Zinc Supplementation in men on semen quality and live birth among couples undergoing infertility treatment. A randomized clinical trial. JAMA 2020;232:35-48.
24. Schubert M, Lanuza LP, Gromoll J. Pharmacogenetics of FSH action in the male. Front Endocrinol 2019; https://doi.org/10.3389/fendo.2019.00047. eCollection 2019
25. Schubert M, Pérez Lanuza L, Wöste M, Dugas M, Carmona FD, Palomino-Morales RJ, RassamY, Heilmann-Heimbach S, Tüttelmann F, Kliesch S, Gromoll J. A GWAS in idiopathic/unexplained infertile men detects a genomic region determing follicle- stimulating hormone levels. Journal Clinical Endocrinoloy & Metabolism, 2022, 107:2350-2361
26. Toure A, Martinez G, Kherraf ZE, Cazin C, Beurois J, Arnoult C, Ray PF, Coutton C. The genetic architecture of morphological abnormalities of the sperm tail. Hum Genet 2021; 140: 21-42
27. Tüttelmann F, Ruckert C, Röpke A. Disorders of spermatogenesis: Perspectives for novel genetic diagnostics after 20 years of unchanged routine. Med Genet. 2018;30(1):12-20. https://doi.org/10.1007/s11825-018-0181-7.
28. Uvin V, De Brucker S, De Brucker M, Vloeberghs V, Drakopoulos P, Santos-Ribeiro S, Tournaye H. Pregnancy after vasectomy: surgical reversal or assisted reproduction. Hum Reprod. 2018; 33:1218-1227
29. Verdi A, Nasr-Esfahani MH, Forouzanfar M, Tavalaee M. The effect of recombinant human follicle-stimulating hormone on sperm quality, chromatin structure and clinical outcomes of infertile oligozoospermic men candidate for intracytoplasmic sperm injection: A randomized clinical trial. Int J Fertil Steril 2021;15:1-7
30. Wensink MJ, Lu Y, Tian L, Shaw GM, Rizzi S, Kold Jensen T, Mathiesen ER, Skakkebaek NE, Lindahl-Jacobsen R, Eisenber ml. Preconception antidiabetic Drugs in men and birth defects in offspring. Ann Intern Med 2022, 175: https://doi.org/10.7326/M21-4389.
31. Wittert G, Bracken K, Robledo KP, Grossmann M, Yeap BB, Handelsman DJ, Stuckey B, Conway A, Inder W, McLachlan R, Allan C, Jesudason D, Fui MNT, Hague W, Jenkins A, Daniel M, Gebski V, Keech A. Testosterone treatment to prevent or revert type 2 diabetes in men enrolled in a lifestyle programme (T4DM): a randomized, double-blind, placebo-controlled, 2-year, phase 3b trial. Lancet Diabetes Endocrinol 2021; 9:32-45.
32. World Health Organization (WHO) Laboratory manual for examination and processing of human semen. 2021; 6. Aufl. WHO, Geneva. WHO laboratory manual for the examination and processing of human semen https://www.who.int/publications/i/item/9789240030787.
33. Wyrwoll MJ, Temel SG, Nagimaja L, OUd MS; Lopes AM, van der Heijden GW, Heald JS, Rotte N, Wistuba J, Wöste M, Ledig S, Krenz H, Smits RM, Carvalho F, Concalves J, Fietz D, Türkgenc, et al. Bi-allelic mutations in M1AP are a frequent cause of meiotic arrest and severely impaired spermatogenesis leading to male infertility. Am J Hum Genet 2020;107:342-351.
34. Wyrwoll MJ, Köckerling N, Vockel M, Dicke AK, Rotte N,Pohl E, Emich J, Wöste M, Ruckert C, Wabschke R, Seggewiss J, Ledig S, Tewes AC, Stratis Y, Cremers JF, Wistuba J, KRallmann C, Kliesch S, Röpke A, Stallmeyer B, Friedrich C, Tüttelmann F. Genetic Architecture of Azoospermia – Time to advance the standard of care. Eur Urol 2022, https://doi.org/10.1016/j.eururo.2022.05.011.
35. Yatsenko AN, Georgiadis AP, Röpke A, Berman AJ, Jaffe T, Olszewska M, Westernströer B, Sanfillippo J, Kurpisz M, Rajkovic A, Yatsenko SA, Kliesch S, Schlatt S, Tüttelmann F. X- linked TEX 11 mutations, meiotic arrest and azoospermia in infertile men. N Engl J Med 2015; 372:2097-2107
36. Zitzmann M, Aksglaede L, Corona G, Isidori AM, Juul A, T ́Sjoen G, Kliesch S, D ́Hauwers K, Toppari J, Slowikoska-Hilczer J, Tüttelmann F, Ferlin A. Academy of Andrology Guidelines on Klinefelter Syndrome. Andrology 2021; 9: 145- 167
37. Zitzmann M, Cremers JF, Krallmann C, Kliesch S. The HEAT-Registry (HEmatopoietic Affection by Testosteron): comparison of a transdermal gel vs long-acting intramuscular testosterone undecanoate in hypogonadal men. The Aging Male 2022; 25:134-144

1. Moolhuijsen, L.M.E., et al. Association between an AMH promoter polymorphism and serum AMH levels in PCOS patients. Hum Reprod. 2022. https://doi.org/10.1093/humrep/deac082.
2. Nguyen, D.K., et al. The predictive value of anti-Mullerian hormone for natural conception leading to live birth in subfertile couples. Reprod Biomed Online. 2022; 44: 557-564.
3. Qiu, W., et al. Anti-Mullerian hormone has limited ability to predict fecundability in Chinese women: a preconception cohort study. https://doi.org/10.1016/j.rbmo.2022.02.014.
Reprod Biomed Online. 2022. 4. Falzarano, C., et al. Nonalcoholic Fatty Liver Disease in Women and Girls With Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2022; 107: 258-272.
5. Cho, I.Y., et al. Long or Irregular Menstrual Cycles and Risk of Prevalent and Incident Nonalcoholic Fatty Liver Disease. J Clin Endocrinol Metab. 2022; 107: e2309-e2317.
6. Berni, T.R., C.L. Morgan, and D.A. Rees Women With Polycystic Ovary Syndrome Have an Increased Risk of Major Cardiovascular Events: a Population Study. J Clin Endocrinol Metab. 2021; 106: e3369-e3380.
7. Duijkers, I.J.M., et al. Effect on ovarian activity and ovulation inhibition of different oral dosages of levonorgestrel. Contraception. 2022; 110: 6-15.
8. Thompson, R.L., et al. The use of serum segesterone acetate levels to assess adherence of trial participants with a contraceptive vaginal ring. Contraception. 2022; 108: 61-64.
9. Reed, S., et al. Unintended pregnancy in users of nomegestrol acetate and 17β-oestradiol (NOMAC-E2) compared with levonorgestrel-containing combined oral contraceptives: final results from the PRO-E2 study. Eur J Contracept Reprod Health Care. 2021; 26: 447-453.
10. Reed, S., et al. Prospective controlled cohort study on the safety of a monophasic oral contraceptive containing nomegestrol acetate (2.5mg) and 17β-oestradiol (1.5mg) (PRO-E2 study): risk of venous and arterial thromboembolism. Eur J Contracept Reprod Health Care. 2021; 26: 439-446.
11. Li, J., et al. Association of Risk for Venous Thromboembolism With Use of Low-Dose Extended- and Continuous-Cycle Combined Oral Contraceptives: A Safety Study Using the Sentinel Distributed Database. JAMA internal medicine. 2018; 178: 1482-1488.
12. Kaplan, S., et al. Long-term safety of extended levonorgestrel-containing oral contraceptives in the United States. Contraception. 2022; 105: 26-32.
13. Goldenberg, I., et al. Use of oral contraceptives in women with congenital long QT syndrome. Heart Rhythm. 2021. https://doi.org/10.1016/j.hrthm.2021.07.058.
14. Karlsson, T., et al. Time-Dependent Effects of Oral Contraceptive Use on Breast, Ovarian, and Endometrial Cancers. Cancer Res. 2021; 81: 1153-1162.
15. Kanadys, W., et al. Use of Oral Contraceptives as a Potential Risk Factor for Breast Cancer: A Systematic Review and Meta-Analysis of Case-Control Studies Up to 2010. Int J Environ Res Public Health. 2021; 18. https://doi.org/10.3390/ijerph18094638.
16. O'Laughlin, D.J., et al. Bleeding Complications Associated With Intrauterine Contraception in Women Receiving Anticoagulation Therapy. Mayo Clin Proc Innov Qual Outcomes. 2022; 6: 98-105.
17. Wu, K.C., et al. FSH Level and Changes in Bone Mass and Body Composition in Older Women and Men. J Clin Endocrinol Metab. 2021; 106: 2876-2889.
18. Madika, A.L., et al. Menopausal hormone therapy and risk of incident hypertension: role of the route of estrogen administration and progestogens in the E3N cohort. Menopause. 2021; 28: 1204-1208.
19. Greendale, G.A., et al. Changes in Regional Fat Distribution and Anthropometric Measures Across the Menopause Transition. J Clin Endocrinol Metab. 2021; 106: 2520-2534.
20. Leite, G., et al. Duodenal microbiome changes in postmenopausal women: effects of hormone therapy and implications for cardiovascular risk. Menopause. 2022; 29: 264-275.
21. Ahmed, F., et al. Role of Estrogen and Its Receptors in Adipose Tissue Glucose Metabolism in Pre- and Postmenopausal Women. J Clin Endocrinol Metab. 2022; 107: e1879-e1889.
22. Shieh, A., et al. Associations of Age at Menopause With Postmenopausal Bone Mineral Density and Fracture Risk in Women. J Clin Endocrinol Metab. 2022; 107: e561-e569.
23. Clark, A.L. Overactive bladder, stress urinary incontinence, and menopause-what are the associations? Menopause. 2022; 29: 125-126.
24. Oliva, A., et al. Resilience and sexual health among menopausal women: a cross-sectional study. Menopause. 2022; 29: 408-414.
25. Kocak, D.Y. and Y. Varisoglu The effect of music therapy on menopausal symptoms and depression: a randomized-controlled study. Menopause. 2022; 29: 545-552.
26. Blondon, M., et al. Comparative venous thromboembolic safety of oral and transdermal postmenopausal hormone therapies among women Veterans. Menopause. 2021; 28: 1125- 1129.
27. Sobel, T.H. and W. Shen Transdermal estrogen therapy in menopausal women at increased risk for thrombotic events: a scoping review. Menopause. 2022; 29: 483-490.
28. Mittal, M., et al. The effect of micronized progesterone and medroxyprogesterone acetate in combination with transdermal estradiol on hemostatic biomarkers in postmenopausal women diagnosed with POI and early menopause: a randomized trial. Menopause. 2022; 29: 580- 589.
29. Kim, J., et al. Oral postmenopausal hormone therapy and genetic risk on venous thromboembolism: gene-hormone interaction results from a large prospective cohort study. Menopause. 2022; 29: 293-303.
30. Cote, D.J., et al. Oral Contraceptive and Menopausal Hormone Therapy Use and Risk of Pituitary Adenoma: Cohort and Case-Control Analyses. J Clin Endocrinol Metab. 2022; 107: e1402-e1412.
31. Wierman, M.E. and K. Kiseljak-Vassiliades Should Dehydroepiandrosterone Be Administered to Women? J Clin Endocrinol Metab. 2022; 107: 1679-1685.
32. Stuenkel, C.A., et al. Approach to the Patient With New-Onset Secondary Amenorrhea: Is This Primary Ovarian Insufficiency? J Clin Endocrinol Metab. 2022; 107: 825-835.
33. Silven, H., et al. Incidence and familial risk of premature ovarian insufficiency in the Finnish female population. Hum Reprod. 2022; 37: 1030-1036.
34. Wang, Z., et al. A meta-analysis of serum lipid profiles in premature ovarian insufficiency. Reprod Biomed Online. 2022; 44: 539-547.
35. Fine, A., et al. Comparing estrogen-based hormonal contraceptives and hormone therapy on bone mineral density in women with premature ovarian insufficiency: a systematic review. Menopause. 2022; 29: 351-359.
36. Goncalves, C.R., et al. Hormone therapy in women with premature ovarian insufficiency: a systematic review and meta-analysis. Reprod Biomed Online. 2022 Jun;44(6):1143-1157. https://doi.org/10.1016/j.rbmo.2022.02.006.
37. King, B., et al. Two Phase 3 Trials of Baricitinib for Alopecia Areata. N Engl J Med. 2022; 386: 1687-1699.
38. Messenger, A. and M. Harries Baricitinib in Alopecia Areata. N Engl J Med. 2022; 386: 1751- 1752.
39. Lawrenz, B. and H.M. Fatemi Are serum progesterone measurements truly representative for the identification of an adequate luteal phase in hormonal replacement therapy frozen embryo transfers? Hum Reprod. 2022; 37: 639-643.
40. Kim, T.H., et al. Role of SIRT1 and Progesterone Resistance in Normal and Abnormal Endometrium. J Clin Endocrinol Metab. 2022; 107: 788-800.
41. Wu, C.Q., et al. Preterm birth after recurrent pregnancy loss: a systematic review and meta- analysis. Fertil Steril. 2022; 117: 811-819.
42. Harada, T., et al. Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain compared with leuprorelin in Japanese women: a phase 3, randomized, double-blind, noninferiority study. Fertil Steril. 2022; 117: 583-592.
43. Lindquist, S., et al. Fertility drugs and incidence of thyroid cancer in a Danish nationwide cohort of 146 024 infertile women. Hum Reprod. 2022; 37: 838-847.

1. ICD-11 for Mortality and Morbidity Statistics. Accessed July 20,2022.
2. Morgan Jules. Trans* health: “diversity, not pathology.” The lancet Psychiatry. 2015;2(2):124- 125. https://doi.org/10.1016/S2215-0366(15)00022-X
3. Winter Sam, Diamond Milton, Green Jamison, Karasic Dan, Reed Terry, Whittle Stephen, Wylie Kevan. Transgender people: health at the margins of society. Lancet (London, England). 2016;388(10042):390-400. https://doi.org/10.1016/S0140-6736(16)00683-8
4. Meyer G, Mayer M, Mondorf A, Herrmann E, Bojunga J. Increasing normality–persisting barriers: Current socio-demographic characteristics of 350 individuals diagnosed with gender dysphoria. Clin Endocrinol (Oxf). 2020;92(3). https://doi.org/10.1111/cen.14140
5. Reisner Sari L, Poteat Tonia, Keatley Jo Anne, Cabral Mauro, Mothopeng Tampose, Dunham Emilia, Holland Claire E, Max Ryan, Baral Stefan D. Global health burden and needs of transgender populations: a review. Lancet. 2016;388(10042):412-436. https://doi.org/10.1016/S0140-6736(16)00684-X
6. De Chants Jonah P, Price Myeshia N, Green Amy E, Davis Carrie K, Pick Casey J. Association of Updating Identification Documents with Suicidal Ideation and Attempts among Transgender and Nonbinary Youth. Int J Environ Res Public Health. 2022;19(9). https://doi.org/10.3390/IJERPH19095016
7. Thoma Brian C, Salk Rachel H, Choukas-Bradley Sophia, Goldstein Tina R, Levine Michele D, Marshal Michael P. Suicidality Disparities Between Transgender and Cisgender Adolescents. Pediatrics. 2019;144(5). https://doi.org/10.1542/PEDS.2019-1183
8. Fouché Tom W, Zakrison Tanya L, Schneider John A, Kaufman Elinore J, Plackett Timothy P, Velopulos Catherine, Slidell Mark B, Voisin Dexter, Hampton David A, Carmichael Heather E, Valdés Davel M, Parker Channyn, Ross Beverly, Chaudhary Mihir, Cirone Justin. Demographic and Regional Factors Associated With Reporting Homicides of Transgender People in the United States. J Surg Res. 2022;279:72-76. https://doi.org/10.1016/J.JSS.2022.05.029
9. Michelson Melissa R, Harrison Brian F. Ties that Bind: The Effects of Transgender Contact on Transphobia. J Homosex. Published online 2022. https://doi.org/10.1080/00918369.2022.2081524
10. Amsalem Doron, Halloran Justin, Penque Brent, Celentano Jillian, Martin Andrés. Effect of a Brief Social Contact Video on Transphobia and Depression-Related Stigma Among Adolescents: A Randomized Clinical Trial. https://doi.org/10.1001/JAMANETWORKOPEN.2022.0376 JAMA Netw open. 2022;5(2).
11. Indremo Malin, Jodensvi Anna Clara, Arinell Hans, Isaksson Johan, Papadopoulos Fotios C. Association of Media Coverage on Transgender Health With Referrals to Child and Adolescent Gender Identity Clinics in Sweden. JAMA Netw open. 2022;5(2). https://doi.org/10.1001/JAMANETWORKOPEN.2021.46531
12. Perales Francisco, Ablaza Christine, Elkin Nicki. Exposure to Inclusive Language and Well- Being at Work Among Transgender Employees in Australia, 2020. Am J Public Health. 2022;112(3):482-490. https://doi.org/10.2105/AJPH.2021.306602
13. van de Cauter Joy, van Schoorisse Hanna, van de Velde Dominique, Motmans Joz, Braeckman Lutgart. Return to work of transgender people: A systematic review through the blender of occupational health. PLoS One. 2021;16(11). https://doi.org/10.1371/JOURNAL.PONE.0259206
14. Kennis Mathilde, Duecker Felix, T’Sjoen Guy, Sack Alexander T, Dewitte Marieke. Gender Affirming Medical Treatment Desire and Treatment Motives in Binary and Non-Binary Transgender Individuals. J Sex Med. 2022;19(7):1173-1184. https://doi.org/10.1016/j.jsxm.2022.03.603
15. Koehler Andreas, Strauss Bernhard, Briken Peer, Szuecs Daria, Nieder Timo O. Centralized and Decentralized Delivery of Transgender Health Care Services: A Systematic Review and a Global Expert Survey in 39 Countries. Front Endocrinol (Lausanne). 2021;12. https://doi.org/10.3389/FENDO.2021.717914
16. Streeter Laer H. Holding Open the Door for Others Like Me. N Engl J Med. 2021;385(7):e27. https://doi.org/10.1056/NEJMPV2111269
17. Santora Tara. How four transgender researchers are improving the health of their communities. Nat Med. 2021;27(12):2074-2077. https://doi.org/10.1038/S41591-021-01597-Y
18. Miyagi Miriam, Guthman Eartha Mae, Sun Simóne Dow Kuang. Transgender rights rely on inclusive language. Science. 2021;374(6575):1568-1569. https://doi.org/10.1126/SCIENCE.ABN3759
19. Pang Ken C, Hoq Monsurul, Steensma Thomas D. Negative Media Coverage as a Barrier to Accessing Care for Transgender Children and Adolescents. JAMA Netw open. 2022;5(2). https://doi.org/10.1001/JAMANETWORKOPEN.2021.38623
20. Stone Louise. Improving care for transgender and non-binary individuals. Nat Rev Urol. 2022;19(6):328. https://doi.org/10.1038/S41585-022-00610-4
21. Cohen Ariel, Gomez-Lobo Veronica. We Are all Responsible for Transgender Care. J Clin Endocrinol Metab. 2022;107(3):E1310-E1311. https://doi.org/10.1210/CLINEM/DGAB723
22. T’Sjoen Guy, Arcelus Jon, Gooren Louis, Klink Daniel T, Tangpricha Vin. Endocrinology of Transgender Medicine. Endocr Rev. 2019;40(1):97-117. https://doi.org/10.1210/er.2018-00011
23. Wiepjes Chantal M, Nota Nienke M, de Blok Christel JM, Klaver Maartje, de Vries Annelou LC, Wensing-Kruger S Annelijn, de Jongh Renate T, Bouman Mark Bram, Steensma Thomas D, Cohen-Kettenis Peggy, Gooren Louis JG, Kreukels Baudewijntje PC, den Heijer Martin. The Amsterdam Cohort of Gender Dysphoria Study (1972–2015): Trends in Prevalence, Treatment, and Regrets. J Sex Med. 2018;15(4):582-590. https://doi.org/10.1016/j.jsxm.2018.01.016
24. Roberts Christina M, Klein David A, Adirim Terry A, Schvey Natasha A, Hisle-Gorman Elizabeth. Continuation of gender-affirming hormones among transgender adolescents and adults. J Clin Endocrinol Metab. Published online April 22, 2022. https://doi.org/10.1210/CLINEM/DGAC251
25. Olson Kristina R, Durwood Lily, Horton Rachel, Gallagher Natalie M, Devor Aaron. Gender Identity 5 Years After Social Transition. Pediatrics. Published online May 4, 2022. https://doi.org/10.1542/peds.2021-056082
26. Zaliznyak Michael, Yuan Nance, Bresee Catherine, Freedman Andrew, Garcia Maurice M. How Early in Life do Transgender Adults Begin to Experience Gender Dysphoria? Why This Matters for Patients, Providers, and for Our Healthcare System. Sex Med. 2021;9(6). https://doi.org/10.1016/J.ESXM.2021.100448
27. Pang Ken C, Feldman Debi, Oertel Ralph, Telfer Michelle. Molecular Karyotyping in Children and Adolescents with Gender Dysphoria. Transgender Heal. 2018;3(1):147-153. https://doi.org/10.1089/trgh.2017.0051
28. Liang Bonnie, Cheung Ada S, Nolan Brendan J. Clinical features and prevalence of Klinefelter syndrome in transgender individuals: A systematic review. Clin Endocrinol (Oxf). 2022;97(1). https://doi.org/10.1111/CEN.14734
29. Huser Nicole, Hulswit Bailey B, Koeller Diane R, Yashar Beverly M. Improving gender- affirming care in genetic counseling: Using educational tools that amplify transgender and/or gender non-binary community voices. J Genet Couns. Published online April 23, 2022. https://doi.org/10.1002/jgc4.1581
30. Ferrucci Katarina A, Lapane Kate L, Jesdale Bill M. Prevalence of diagnosed eating disorders in US transgender adults and youth in insurance claims. Int J Eat Disord. 2022;55(6):801- 809. https://doi.org/10.1002/EAT.23729
31. Simone Melissa, Hazzard Vivienne M, Askew Autumn J, Tebbe Elliot A, Lipson Sarah K, Pisetsky Emily M. Variability in eating disorder risk and diagnosis in transgender and gender diverse college students. Ann Epidemiol. 2022;70:53-60. https://doi.org/10.1016/J.ANNEPIDEM.2022.04.007
32. Moradi Ghobad, Soheili Marzieh, Rashti Roya, Dehghanbanadaki Hojat, Nouri Elham, Zakaryaei Farima, Amini Elnaz Ezzati, Baiezeedi Sheno, Ahmadi Sanaz, Moradi Yousef. The prevalence of hepatitis C and hepatitis B in lesbian, gay, bisexual and transgender populations: a systematic review and meta-analysis. Eur J Med Res. 2022;27(1). https://doi.org/10.1186/S40001-022-00677-0
33. Cooper Holly C, Long Jin, Aye Tandy. Fertility preservation in transgender and non- binary adolescents and young adults. PLoS One. 2022;17(3). https://doi.org/10.1371/JOURNAL.PONE.0265043
34. Douglas Christopher R, Phillips Destiny, Sokalska Anna, Aghajanova Lusine. Fertility Preservation for Transgender Males: Counseling and Timing of Treatment. Obstet Gynecol. 2022;139(6):1012-1017. https://doi.org/10.1097/AOG.0000000000004751
35. Roberts Christina. Persistence of Transgender Gender Identity Among Children and Adolescents. Pediatrics. Published online May 11, 2022. https://doi.org/10.1542/PEDS.2022-057693
36. Irwig Michael S. Detransition among transgender and gender diverse people - an increasing and increasingly complex phenomenon. J Clin Endocrinol Metab. Published online June 9, 2022. https://doi.org/10.1210/CLINEM/DGAC356
37. Meyer Gesine, Boczek Ute, Bojunga Jörg. Hormonal gender reassignment treatment for gender dysphoria. Dtsch Arztebl Int. 2020;117(43):725-732. https://doi.org/10.3238/arztebl.2020.0725
38. O’Connell Michele A, Nguyen Thomas P, Ahler Astrid, Skinner S Rachel, Pang Ken C. Approach to the Patient: Pharmacological Management of Trans and Gender-Diverse Adolescents. J Clin Endocrinol Metab. 2022;107(1):241-257. https://doi.org/10.1210/CLINEM/DGAB634
39. D’hoore Laurens, T’Sjoen Guy. Gender-affirming hormone therapy: An updated literature review with an eye on the future. J Intern Med. 2022;291(5):574-592. https://doi.org/10.1111/JOIM.13441
40. Dahlen Sara, Connolly Dean, Arif Isra, Junejo Muhammad Hyder, Bewley Susan, Meads Catherine. International clinical practice guidelines for gender minority/trans people: systematic review and quality assessment. BMJ Open. 2021;11(4). https://doi.org/10.1136/BMJOPEN-2021-048943
41. Milionis Charalampos, Ilias Ioannis, Koukkou Eftychia. Progesterone in gender-affirming therapy of trans women. World J Biol Chem. 2022;13(3):66-71. https://doi.org/10.4331/WJBC.V13.I3.66
42. Nolan Brendan J, Frydman Aviva S, Leemaqz Shalem Y, Carroll Meg, Grossmann Mathis, Zajac Jeffrey D, Cheung Ada S. Effects of low-dose oral micronised progesterone on sleep, psychological distress, and breast development in transgender individuals undergoing feminising hormone therapy: a prospective controlled study. Endocr Connect. 2022;11(5). https://doi.org/10.1530/EC-22-0170
43. Meyer G, Mayer M, Mondorf A, Flügel AK, Herrmann E, Bojunga J. Safety and rapid efficacy of guideline-based gender-affirming hormone therapy: An analysis of 388 individuals diagnosed with gender dysphoria. Eur J Endocrinol. 2020;182(2). https://doi.org/10.1530/EJE-19-0463
44. Grimstad Frances, Kremen Jessica, Shim Jessica, Charlton Brittany M, Boskey Elizabeth R. Breakthrough Bleeding in Transgender and Gender Diverse Adolescents and Young Adults on Long-T erm T estosterone. J Pediatr Adolesc Gynecol. 2021;34(5):706-716. https://doi.org/10.1016/J.JPAG.2021.04.004
45. Tordoff Diana M, Wanta Jonathon W, Collin Arin, Stepney Cesalie, Inwards-Breland David J, Ahrens Kym. Mental Health Outcomes in Transgender and Nonbinary Youths Receiving Gender-Affirming Care. JAMA Netw open. 2022;5(2):e220978. https://doi.org/10.1001/JAMANETWORKOPEN.2022.0978
46. Yelehe Melissa, Klein Marc, El Aridi Layal, Maurier Anaïs, Gillet Pierre, Feigerlova Eva. Adverse effects of gender-affirming hormonal therapy in transgender persons: Assessing reports in the French pharmacovigilance database. Fundam Clin Pharmacol. Published online June 6, 2022. https://doi.org/10.1111/FCP.12806
47. Glintborg Dorte, Rubin Katrine Hass, Kristensen Simon Bang, Lidegaard Øjvind, T’Sjoen Guy, Hilden Malene, Andersen Marianne Skovsager. Gender affirming hormonal treatment in Danish transgender persons: A nationwide register-based study. Andrology. 2022;10(5). https://doi.org/10.1111/ANDR.13181
48. Karalexi Maria A, Frisell Thomas, Cnattingius Sven, Holmberg Dag, Holmberg Mats, Kollia Natasa, Skalkidou Alkistis, Papadopoulos Fotios C. Cardiovascular outcomes in transgender individuals in Sweden after initiation of gender-affirming hormone therapy. Eur J Prev Cardiol. Published online July 2, 2022. https://doi.org/10.1093/EURJPC/ZWAC133
49. Ong Caroline, Liu Minghao, Thermidor Sadiya, Eid Marwen, Gianos Eugenia. Transgender Cardiovascular Health: Practical Management for the Clinician. Curr Atheroscler Rep. Published online June 29, 2022. https://doi.org/10.1007/S11883-022-01047-1
50. Aldridge Zoë, Patel Shireen, Guo Boliang, Nixon Elena, Pierre Bouman Walter, Witcomb Gemma L, Arcelus Jon. Long-term effect of gender-affirming hormone treatment on depression and anxiety symptoms in transgender people: A prospective cohort study. Andrology. 2021;9(6):1808-1816. https://doi.org/10.1111/andr.12884
51. Silva Eliane D, Fighera Tayane M, Allgayer Roberta M, Lobato Maria Inês R, Spritzer Poli Mara. Physical and Sociodemographic Features Associated With Quality of Life Among Transgender Women and Men Using Gender-Affirming Hormone Therapy. Front psychiatry. 2021;12:621075. https://doi.org/10.3389/fpsyt.2021.621075
52. Giacomelli Giulia, Meriggiola Maria Cristina. Bone health in transgender people: a narrative review. Ther Adv Endocrinol Metab. 2022;13:204201882210993. https://doi.org/10.1177/20420188221099346
53. Van Velzen Daan, Wiepjes Chantal, Nota Nienke, Van Raalte Daniel, De Mutsert Renée, Simsek Suat, Den Heijer Martin. Incident Diabetes Risk Is Not Increased in Transgender Individuals Using Hormone Therapy. J Clin Endocrinol Metab. 2022;107(5):E2000- E2007. https://doi.org/10.1210/CLINEM/DGAB934
54. de Blok Christel JM, Dreijerink Koen MA, den Heijer Martin. Cancer Risk in Transgender People. Endocrinol Metab Clin North Am. 2019;48(2):441-452. https://doi.org/10.1016/J.ECL.2019.02.005
55. Li Virginia Y, Demzik Alysen, Snyder Liem, Ogunleye Adeyemi A, Wang Annmarie, Figler Bradley D. Genital Gender Affirming Surgery. Am Surg. Published online June 28, 2022:000313482211094. https://doi.org/10.1177/00031348221109479
56. Awe Adam M, Burkbauer Laura, Pascarella Luigi. Surgical Implications of LGBTQ+ Health Disparities: A Review. Am Surg. Published online 2022. https://doi.org/10.1177/00031348221096577
57. Almazan Anthony N, Keuroghlian Alex S. Association Between Gender-Affirming Surgeries and Mental Health Outcomes. JAMA Surg. 2021;156(7):611-618. https://doi.org/10.1001/JAMASURG.2021.0952
58. Pitak-Arnnop Poramate, Messer-Peti Robert, T angmanee Chatpong, Neff Andreas, Meningaud Jean Paul. Prostate cancer awareness among transgender women after gender- affirming surgery. Prostate. 2022;82(10):1060-1067. https://doi.org/10.1002/PROS.24355
59. Shin Sangyoon Jason, Kumar Anish, Safer Joshua D. Gender-Affirming Surgery: Perioperative Medical Care. https://doi.org/10.1016/J.EPRAC.2022.02.007 Endocr Pract. 2022;28(4):420-424.
60. Wu Shannon S, Raymer Charles A, Kaufman Bram R, Isakov Raymond, Ferrando Cecile A. The Effect of Preoperative Gender Affirming Hormone Therapy Use on Perioperative Adverse Events in Transmasculine Individuals Undergoing Masculinizing Chest Surgery for Gender Affirmation. Aesthetic Surg J. Published online April 13, 2022. https://doi.org/10.1093/ASJ/SJAC091
61. Kozato Aki, Conner Fox GW, Yong Patrick C, Shin Sangyoon J, Avanessian Bella K, Ting Jess, Ling Yiwei, Karim Subha, Safer Joshua D, Pang John Henry. No Venous Thromboembolism Increase Among Transgender Female Patients Remaining on Estrogen for Gender-Affirming Surgery. J Clin Endocrinol Metab. 2021;106(4):E1586- E1590. https://doi.org/10.1210/CLINEM/DGAA966
62. Badreddine J, Lee MH, Mishra K, Pope R, Kim JY, Hong SH, Gupta S, Song JM, Shin Jae Il, Ghayda RA. Continuing perioperative estrogen therapy does not increase venous thromboembolic events in transgender patients: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2022;26(7):2511-2517. https://doi.org/10.26355/EURREV_202204_28488
63. Safer Joshua D, Tangpricha Vin. Care of Transgender Persons. N Engl J Med. 2019;381(25):2451-2460. https://doi.org/10.1056/NEJMcp1903650

A) Diabetes

1. EASD 2021. Session: OP 07 When men are mice: the study of human physiology in humans Oral Presentation # 41 Pathophysiological changes during weight-loss induced remission of type 2 diabetes in non-obese people.
2. Holman N, Wild SH, Khunti K et al. Incidence and Characteristics of Remission of Type 2 Diabetes in England: A Cohort Study Using the National Diabetes Audit. Diabetes Care 2022;45(5):1151–1161 https://doi.org/10.2337/dc21-2136.
3. RFGCORChuruangsuk C, Hall J, Reynolds A et al. Diets for weight management in adults with type 2 diabetes: an umbrella review of published meta-analyses and systematic review of trials of diets for diabetes remission. Diabetologia 65, 14–36 (2022). https://doi.org/10.1007/s00125-021-05577-2.
4. Thom G, Messow CM, Leslie WS et al (2021) Predictors of type 2 diabetes remission in the diabetes remission clinical trial (DiRECT). Diabet Med 38(8):e14395. https://doi.org/10.1111/dme.14395
5. McArdle PD, Greenfield SM, Rilstone SK et al. Carbohydrate restriction for glycaemic control in type 2 diabetes: a systematic review and meta-analysis. Diabet Med 36(3):335– 348. https://doi.org/10.1111/dme.13862
6. Goldenberg JZ, Day A, Brinkworth GD et al (2021) Efficacy and safety of low and very low carbohydrate diets for type 2 diabetes remission: systematic review and meta-analysis of published and unpublished randomized trial data. BMJ 372:m4743. https://doi.org/10.1136/bmj.m4743
7. Vitale R, Kim Y (2020) The effects of intermittent fasting on glycemic control and body composition in adults with obesity and type 2 diabetes: a systematic review. Metab Syndr Relat Disord 18(10):450–461. https://doi.org/10.1089/met.2020.0048
8. Choi IY, Chang Y, Cho Y et al. Prediabetes diagnosis is associated with the progression of coronary artery calcification: the Kangbuk Samsung Health Study Diabetes Obes Metab. 2022 Jun 13. https://doi.org/10.1111/dom.14797
Online ahead of print. 9. Pigeyre, M., Hess, S., Gomez, M.F. et al Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial. Diabetologia 65, 206–215 (2022) https://doi.org/10.1007/s00125-021-05567-4.
10. The ORIGIN Trial Investigators. Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia. July 26, 2012 N Engl J Med 2012; 367:319-328 https://doi.org/10.1056/NEJMoa1203858.
11. Rathmann W, Kuss O, Kostev K. Incidence of newly diagnosed diabetes after Covid-19 Diabetologia volume 65, pages949–954 (2022), https://doi.org/10.1007/s00125-022-05670-0.
12. Yoshida Y, Chen Z, Baudier RL et al. Early Menopause and Cardiovascular Disease Risk in Women With or Without Type 2 Diabetes: A Pooled Analysis of 9,374 Postmenopausal Women Diabetes Care 2021;44(11):2564–2572 https://doi.org/10.2337/dc21-1107.
13. Brand KMG, Saarelainen L, Sonajalg J et al. Metformin in pregnancy and risk of adverse long- term outcomes: a register-based cohort study BMJ Open Diabetes Res Care.2022 Jan;10(1):e002363. https://doi.org/10.1136/bmjdrc-2021-002363
14. Estrella J, Wiley V, Simmons D et al. Effect of Maternal Metformin Treatment in Pregnancy on Neonatal Metabolism: Evidence From Newborn Metabolic Screening Diabetes Care 2021;44(11):2536–2541 https://doi.org/10.2337/dc21-0327.
15. Diaz-Sant, O’Brien KM, Mark Park YM et al. of Risk for Type 2 Diabetes After Gestational Diabetes Mellitus Diabetes Care 2022;45(4):864–870 https://doi.org/10.2337/dc21-1430.
16. Insulin Icodec studien Programm PR 220427 NN https://www.novonordisk.com/news-and- media/news-and-ir-materials.html.
17. Bajaj HS, Bergenstal RM, Christoffersen A et al. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial. Diabetes Care. 2021 Jul;44(7):1586-1594. https://doi.org/10.2337/dc20-2877. Epub 2021 Apr 19.PMID: 33875485 Free PMC article. Clinical Trial.
18. Lingvay I, Buse JB, Franek E et al. A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. Diabetes Care. 2021 Jul;44(7):1595-1603. https://doi.org/10.2337/dc20-2878. Epub 2021 Apr 19.PMID: 33875484 Free PMC article. Clinical Trial.
19. Kjeldsen TB, Hubálek F, Hjørringgaard CU et al. Molecular Engineering of Insulin Icodec, the First Acylated Insulin Analog for Once-Weekly Administration in Humans. Med Chem. 2021 Jul 8;64(13):8942-8950. https://doi.org/10.1021/acs.jmedchem.1c00257. Epub 2021 May 4. PMID: 33944562 Free article.
20. Svehlikova E, Niss Arfelt K, Cailleteau R et al. Hypoglycemia Frequency and Physiological Response to Double or Triple Doses of Once-Weekly Insulin Icodec vs Once-Daily Insulin Glargine in Type 2 Diabetes Presented at ADA June 5th, 2022.
21. Blue-Valleskey JM, Kazda CM, Ma c et al. Once Weekly (QW) Basal Insulin Fc (BIF) Demonstrated Similar Glycemic Control to Once Daily Insulin Degludec in Insulinnaïve Patients with Type 2 Diabetes (T2D) American Diabetes Association - 82nd Annual Scientific Sessions; New Orleans, LA, USA; 3 – 7 June 2022.
22. Zucker, I., Zloof, Y., Bardugo, A. et al. Obesity in late adolescence and incident type 1 diabetes in young adulthood. Diabetologia (2022). https://doi.org/10.1007/s00125-022-05722-5
23. Grauslund J. Diabetic retinopathy screening in the emerging era of artificial intelligence. Diabetologia 2022: 65, 1415–1423. https://doi.org/10.1007/s00125-022-05727-0
24. Roser P, Grohmann C, Aberle J et al. Evaluation der Implementierung eines zugelassenen Künstliche-Intelligenz-Systems zur Erkennung der diabetischen Retinopathie Diabetologie und Stoffwechsel 2021; 16(05): 402-208. https://doi.org/10.1055/a-1484-9678
25. Sheikh A, Bhatti A, Adeyemi O, Raja M, Sheikh I (2021) The Utility of Smartphone-Based Artificial Intelligence Approaches for Diabetic Retinopathy: A Literature Review and Meta- Analysis. J Curr Ophthalmol 33(3):219–226. https://doi.org/10.4103/2452-2325.329064
26. Zhang W, Nicholas P, Schuman SG et al (2017) Screening for Diabetic Retinopathy Using a Portable, Noncontact, Nonmydriatic Handheld Retinal Camera. J Diabetes Sci Technol 11(1):128–134. https://doi.org/10.1177/1932296816658902
27. Piyasena M, Yip JLY, MacLeod D et al. (2019) Diagnostic test accuracy of diabetic retinopathy screening by physician graders using a hand-held non-mydriatic retinal camera at a tertiary level medical clinic. BMC Ophthalmol 19(1):89. https://doi.org/10.1186/s12886-019-1092-3
28. Mutter S, Valo E, Aittomäki V et a. Urinary metabolite profiling and risk of progression of diabetic nephropathy in 2670 individuals with type 1 diabetes. Diabetologia 65, 140–149 (2022). https://doi.org/10.1007/s00125-021-05584-3
29. Heerspink, HL, Sattar N, Pavo I et al. Once-per-week tirzepatide compared to [daily] insulin glargine treatment resulted in a meaningful improvement in estimated glomerular filtration rate (eGFR) decline and reduced urine albumin-to-creatinine ratio (UACR) and the risk of end-stage kidney disease (ESKD) American Diabetes Association -82nd Annual Scientific Sessions; New Orleans, LA, USA; 3 –7 June 2022.
30. Lingvay I, Mosenzon O, Brown K et al. Systolic Blood Pressure Reduction with Tirzepatide across SURPASS Program: A Mediation Analysis Using Weight Loss as a Factor ADA Scientific Sessions 2022. Clinical Therapeutics/New Technology - Incretin-Based Therapies Presented on Sunday, June 5, 2022 12:00 PM. 176-P.
31. Miller RG, Orchard TJ, Costacou T. 30-Year Cardiovascular Disease in Type 1 Diabetes: Risk and Risk Factors Differ by Long-term Patterns of Glycemic Control. Diabetes Care 2022;45(1):142–150, https://doi.org/10.2337/dc21-1381.
32. Martens TW. Overcoming Inertia- Using CGM to Facilitate effective insulin titration in people with type 2 diabetes on basal-insulin of basal-bolus insulin regimens. Präsentiert auf dem American Diabetes Association 82nd Scientific Sessions – New Orleans and Virtual, June 3- 7, 2022; 3-CT-SY15. Symposium – New Strategies for Insulin use in Type 2 Diabetes.
33. The Insulin-Only Bionic Pancreas Pivotal Trial Presented at ADA 2022 Juni 3, 13:4514:45. The Bihormonal Bionic Pancreas Improves Glycemic Control in Individuals With Hyperinsulinism and Postpancreatectomy Diabetes: A Pilot Study Diabetes Care 2021;44(11):2582–2585, https://doi.org/10.2337/dc21-0416.
34. Secher AL, Pedersen-Bjergaard U, Svendsen OL et al. Flash glucose monitoring and automated bolus calculation in type 1 diabetes treated with multiple daily insulin injections: a 26 week randomised, controlled, multicentre trial. Diabetologia 64, 2713–2724 (2021). https://doi.org/10.1007/s00125-021-05555-8
35. Aleppo G, Beck R, Bailey R et al. The Effect of Discontinuing Continuous Glucose Monitoring in Adults With Type 2 Diabetes Treated With Basal Insulin Diabetes Care 2021;44(12):2729– 2737 https://doi.org/10.2337/dc21-1304.
36. Sherr JL, Bode BW, Forlenza GP et al. Safety and Glycemic Outcomes With a Tubeless Automated Insulin Delivery System in Very Young Children With Type 1 Diabetes: A Single- Arm Multicenter Clinical Trial. Diabetes Care dc212359 https://doi.org/10.2337/dc21-2359.
37. Holt RIG, DeVries JH, Hess-Fischl A et al, The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) https://doi.org/10.1007/s00125-021-05568-3.
38. Diabetologia 64, 2609–2652 (2021).
39. Aroda VR, Krause-Steinrauf H, Kazemi EJ et al, Clinical and Metabolic Characterization of Adults With Type 2 Diabetes by Age in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE) Cohort. Diabetes Caredc212659, https://doi.org/10.2337/dc21-2659.
40. Feron F, Pean de Ponfilly P, Potier L et al. Reliability and Safety of Bedside Blind Bone Biopsy Performed by a Diabetologist for the Diagnosis and Treatment of Diabetic Foot Osteomyelitia, Diabetes Care 2021;44(11):2480–2486 https://doi.org/10.2337/dc20-3170.
41. Pop-Busui R, Januzzi JL, Bruemmer D et al. Consensus report: Heart Failure: An Underappreciated Complication of Diabetes. A Consensus Report of the American Diabetes Association. Diabetes Care dci220014 https://doi.org/10.2337/dci22-0014.
42. Echouffo-Tcheugui, JB, Ndumelel CH, Zhang S et al. Diabetes and Progression of Heart Failure: The Atherosclerosis Risk In Communities (ARIC) Study J Am Coll Cardiol. 2022 Jun, 79 (23) 2285–2293. https://doi.org/10.1016/j.jacc.2022.03.378
43. Wright AK, Carr MJ, Kontopantelis E et al. Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes Diabetes Care 2022;45(4):909–918 https://doi.org/10.2337/dc21-1113.
44. Lopez P, Bohra C, Bhatia K. Additive Cardiovascular Risc Reduction of GLP1A and SGLT2I in Diabetes Patients With Atherosclerotic Disease. Presented at ACC 2022. April 4th. Session 915.
45. Marso S, Bain SC, Consoli A et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med2016 Nov 10;375(19):1834-1844. https://doi.org/10.1056/NEJMoa1607141. Epub 2016 Sep 15.
46. Wiviott SD, Raz I, Bonaca N et al Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. Engl J Med 2019; 380:347-357 https://doi.org/10.1056/NEJMoa1812389.
47. Marso SP, Daniels GH, Brown-Frandsen K et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016; 375:311-322. https://doi.org/10.1056/NEJMoa1603827
48. Zinman B, Wanner C, Lachin JM et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373:2117-2128. https://doi.org/10.1056/NEJMoa1504720
49. Williams BA, Brady JP, Voyce S Changes over time in the cardiovascular risk profile of type 2 diabetes from 2007 to 2020: A community-based study Volume24, Issue7 July 2022 Pages 1216-1223 https://doi.org/10.1111/dom.14686.
50. Luchsinger JA, Naji Younes JJM, Manly JB et al. Association of Glycemia, Lipids, and Blood Pressure With Cognitive Performance in People With Type 2 Diabetes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE). Diabetes Care 2021;44(10):2286–2292. https://doi.org/10.2337/dc20-2858
51. EASD/ADA Consensus Statement. Präsentiert auf dem American Diabetes Association 82nd Scientific Sessions – New Orleans and Virtual, June 3-7, 2022; 3-CT-SY17. Joint.
52. T. Karagiannis, et al., Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis. Diabetologia 65, 1251–1261 (2022).
53. B. Ludvik, et al., Once-weekly tirzepatide versus once-daily insulin degludec as add- on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet 398, 583– 598 (2021).
54. T. Battelino, et al., Efficacy of once-weekly tirzepatide versus once-daily insulin degludec on glycaemic control measured by continuous glucose monitoring in adults with type 2 diabetes (SURPASS-3 CGM): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol 10, 407–417 (2022).
55. S. Del Prato, et al., Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. Lancet 398, 1811–1824 (2021).
56. S. URVA, et al., 340-OR: LY3437943 (LY) , a Novel Triple GIP/GLP-1/Glucagon Receptor Agonist, Provides Glucose Lowering and Weight Loss in Patients with T2DM after 12 Weeks of Treatment. Diabetes 71, 340-OR (2022).
57. T. Matsumura, et al., Clinical Benefit of Switching from Low-Dose to High-Dose Empagliflozin in Patients with Type 2 Diabetes. Diabetes Ther (2022) : https://doi.org/10.2337/dc20-2858.
58. M. G. Posch, et al., Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study. Diabetes Care, dc212166 (2022). https://doi.org/10.2337/dc20-2858
59. P. Paolisso, et al., Infarct size, inflammatory burden, and admission hyperglycemia in diabetic patients with acute myocardial infarction treated with SGLT2-inhibitors: a multicenter international registry. Cardiovasc Diabetol 21, 77 (2022).
60. P. Mone, et al., SGLT2 Inhibition via Empagliflozin Improves Endothelial Function and Reduces Mitochondrial Oxidative Stress: Insights From Frail Hypertensive and Diabetic Patients. Hypertension 79, 1633–1643 (2022).
61. D. Tricò, F. Raggi, M. Distaso, E. Ferrannini, A. Solini, Effect of empagliflozin on plasma proprotein convertase subtilisin/kexin type 9 (PCSK9) in patients with type 2 diabetes. Diabetes Res Clin Pract 190, 109983 (2022).
62. A. Cowan, et al., Fracture Risk of Sodium-Glucose Cotransporter-2 Inhibitors in Chronic Kidney Disease. Clin J Am Soc Nephrol 17, 835–842 (2022).
63. Y. Huh, Y. S. Kim, Predictors for successful weight reduction during treatment with Dapagliflozin among patients with type 2 diabetes mellitus in primary care. BMC Prim Care 23, 134 (2022).
64. B. L. Neuen, et al., Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation 145, 1460–1470 (2022).
65. W. V. Tamborlane, et al., Efficacy and safety of dapagliflozin in children and young adults with type 2 diabetes: a prospective, multicentre, randomised, parallel group, phase 3 study. Lancet Diabetes Endocrinol 10, 341–350 (2022).
66. L. G. H. Goh, et al., Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: a retrospective multi- ethnic cohort study. J Diabetes Metab Disord 21, 521–555 (2022).
67. J. W. Sacre, D. J. Magliano, J. E. Shaw, Clinical Utility of Cardiovascular Risk Scores for Identification of People With Type 2 Diabetes More Likely to Benefit From Either GLP-1 Receptor Agonist or SGLT2 Inhibitor Therapy. Diabetes Care, dc211929 (2022). https://doi.org/10.2337/dc21-1929
68. D. T. W. Lui, et al., Kidney outcomes associated with sodium-glucose cotransporter 2 inhibitors versus glucagon-like peptide 1 receptor agonists: A real-world population-based analysis. EClinicalMedicine 50, 101510 (2022). https://doi.org/10.1016/j.eclinm.2022.101510
69. R. Hao, et al., Underuse of cardiorenal protective agents in high-risk diabetes patients in primary care: a cross-sectional study. BMC Prim Care 23, 124 (2022).
70. S. V. Arnold, et al., Global use of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes. Results from DISCOVER. BMC Endocr Disord 22, 111 (2022).
71. J.-H. Lim, et al., The Efficacy and Safety of SGLT2 Inhibitor in Diabetic Kidney Transplant Recipients. Transplantation (2022) https://doi.org/10.1097/TP.0000000000004228
72. K. R. Tuttle, et al., Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care 45, 1445–1452 (2022).
73. I. Idris, et al., Significant reduction in chronic kidney disease progression with sodium-glucose cotransporter-2 inhibitors compared to dipeptidyl peptidase-4 inhibitors in adults with type 2 diabetes in a UK clinical setting: An observational outcomes study based on international guidelines for kidney disease. Diabetes Obes Metab (2022) https://doi.org/10.1111/dom.14799
74. S. C. Goulooze, et al., Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD. Clin Pharmacokinet 61, 1013–1025 (2022).
75. W.-Z. Siao, T.-K. Lin, J.-Y. Huang, C.-F. Tsai, G.-P. Jong, The association between sodium- glucose cotransporter 2 inhibitors and incident dementia: A nationwide population-based longitudinal cohort study. Diab Vasc Dis Res 19, 14791641221098168 (2022).
76. S. Low, et al., Association Between Use of Sodium-Glucose Co-Transporter-2 (SGLT2) Inhibitors and Cognitive Function in a Longitudinal Study of Patients with Type 2 Diabetes. J Alzheimers Dis 87, 635–642 (2022).
77. I. K. Wium-Andersen, M. Osler, M. B. Jørgensen, J. Rungby, M. K. Wium-Andersen, Diabetes, antidiabetic medications and risk of depression - A population-based cohort and nested case-control study. Psychoneuroendocrinology 140, 105715 (2022).

B) Adipositas

1. Balakrishnan VS. Obesity: Europe's obesity burden on the rise: WHO report. Lancet Diabetes Endocrinol. 2022;10:488. Uerlich MF, Yumuk V, Finer N, Basdevant A, Visscher TL. Obesity Management in Europe: Current Status and Objectives for the Future. Obes Facts. 2016;9(4):273-83.
2. Schienkiewitz A, Mensink GBM, Kuhnert R, Lange C. Übergewicht und Adipositas bei Erwachsenen in Deutschland. Journal of Health Monitoring 2017 2, DOI 10.17886/RKI-GBE- 2017-025.
3. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15: 288- 298. Global Obesity Observatory. Germany. Verfügbar unter: https://data.worldobesity.org/country/germany-76/ Letzter Zugriff am 25.07.2022.
4. Aberle J, Lautenbach A, Meyhöfer S, Meyhöfer SM, Selig L, Blüher M, Menzen M. Adipositas und Diabetes. Diabetologie 2022; 18: 418-425.
5. Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, Rothberg AE, le Roux CW, Rubino F, Schauer P, Taylor R, Twenefour D.Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care. 2021; 44: 2438-44.
6. Bemeinsamer Bundesausschuss. G-BA beginnt mit Entwicklung eines DMP Adipositas. https://www.g-ba.de/presse/pressemitteilungen-meldungen/975/ Letzter Zugriff am 25.07.2022.
7. Stefan N. Metabolic disorders, COVID-19 and vaccine-breakthrough infections. Nat Rev Endocrinol. 2022; 18: 75-76.
8. Vogel M, Geserick M, Gausche R, Beger C, Poulain T, Meigen C, Körner A, Keller E, Kiess W, Pfäffle R. Age- and weight group-specific weight gain patterns in children and adolescents during the 15 years before and during the COVID-19 pandemic. Int J Obes (Lond). 2022;46:144-152. Stefan N, Sippel K, Heni M, Fritsche A, Wagner R, Jakob CEM, Preißl H, von Werder A, Khodamoradi Y, Borgmann S, Rüthrich MM, Hanses F, Haselberger M, Piepel C, Hower M, Vom Dahl J, Wille K, Römmele C, Vehreschild J, Stecher M, Solimena M, Roden M, Schürmann A, Gallwitz B, Hrabe de Angelis M, Ludwig DS, Schulze MB, Jensen BEO, Birkenfeld AL. Obesity and Impaired Metabolic Health Increase Risk of COVID-19-Related Mortality in Young and Middle-Aged Adults to the Level Observed in Older People: The LEOSS Registry. Front Med (Lausanne). 2022; 9:875430.
9. Loosen SH, Jensen BO, Tanislav C, Luedde T, Roderburg C, Kostev K. Obesity and lipid metabolism disorders determine the risk for development of long COVID syndrome: a cross- sectional study from 50,402 COVID-19 patients. Infection. 2022 Mar 30:1-6.
10. Reiterer M, Rajan M, Gómez-Banoy N, Lau JD, Gomez-Escobar LG, Ma L, Gilani A, Alvarez- Mulett S, Sholle ET, Chandar V, Bram Y, Hoffman K, Bhardwaj P, Piloco P, Rubio-Navarro A, Uhl S, Carrau L, Houhgton S, Redmond D, Shukla AP, Goyal P, Brown KA, tenOever BR, Alonso LC, Schwartz RE, Schenck EJ, Safford MM, Lo JC. Hyperglycemia in acute COVID- 19 is characterized by insulin resistance and adipose tissue infectivity by SARS-CoV-2. Cell Metab. 2021;33: 2174-2188.e5.
11. Zickler M, Stanelle-Bertram S, Ehret S, Heinrich F, Lange P, Schaumburg B, Kouassi NM, Beck S, Jaeckstein MY, Mann O, Krasemann S, Schroeder M, Jarczak D, Nierhaus A, Kluge S, Peschka M, Schlüter H, Renné T, Pueschel K, Kloetgen A, Scheja L, Ondruschka B, Heeren J, Gabriel G. Replication of SARS-CoV-2 in adipose tissue determines organ and systemic lipid metabolism in hamsters and humans. Cell Metab. 2022 Jan 4;34(1):1-2.
12. Mendes de Oliveira E, Keogh JM, Talbot F, Henning E, Ahmed R, Perdikari A, Bounds R, Wasiluk N, Ayinampudi V, Barroso I, Mokrosiński J, Jyothish D, Lim S, Gupta S, Kershaw M, Matei C, Partha P, Randell T, McAulay A, Wilson LC, Cheetham T, Crowne EC, Clayton P, Farooqi IS. Obesity-Associated GNAS Mutations and the Melanocortin Pathway. N Engl J Med. 2021; 385: 1581-1592.
13. Emont MP, Jacobs C, Essene AL, Pant D, Tenen D, Colleluori G, Di Vincenzo A, Jørgensen AM, Dashti H, Stefek A, McGonagle E, Strobel S, Laber S, Agrawal S, Westcott GP, Kar A, Veregge ML, Gulko A, Srinivasan H, Kramer Z, De Filippis E, Merkel E, Ducie J, Boyd CG, Gourash W, Courcoulas A, Lin SJ, Lee BT, Morris D, Tobias A, Khera AV, Claussnitzer M, Pers TH, Giordano A, Ashenberg O, Regev A, Tsai LT, Rosen ED. A single-cell atlas of human and mouse white adipose tissue. Nature. 2022;603: 926-933.
14. Forslund SK, Chakaroun R, Zimmermann-Kogadeeva M, Markó L, Aron-Wisnewsky J, Nielsen T, Moitinho-Silva L, Schmidt TSB, Falony G, Vieira-Silva S, Adriouch S, Alves RJ, Assmann K, Bastard JP, Birkner T, Caesar R, Chilloux J, Coelho LP, Fezeu L, Galleron N, Helft G, Isnard R, Ji B, Kuhn M, Le Chatelier E, Myridakis A, Olsson L, Pons N, Prifti E, Quinquis B, Roume H, Salem JE, Sokolovska N, Tremaroli V, Valles-Colomer M, Lewinter C, Søndertoft NB, Pedersen HK, Hansen TH; MetaCardis Consortium*, Gøtze JP, Køber L, Vestergaard H, Hansen T, Zucker JD, Hercberg S, Oppert JM, Letunic I, Nielsen J, Bäckhed, Rinott E, Youngster I, Yaskolka Meir A, Tsaban G, Zelicha H, Kaplan A, Knights D, Tuohy K, Fava F, Scholz MU, Ziv O, Reuven E, Tirosh A, Rudich A, Blüher M, Stumvoll M, Ceglarek U, Clement K, Koren O, Wang DD, Hu FB, Stampfer MJ, Shai I. Effects of Diet-Modulated Autologous Fecal Microbiota Transplantation on Weight Regain. Gastroenterology. 2021;160:158-173.
15. Li Z, Zhang B, Wang N, Zuo Z, Wei H, Zhao F. A novel peptide protects against diet-induced obesity by suppressing appetite and modulating the gut microbiota. Gut. 2022 Jul 8:gutjnl- 2022-328035.
16. Müller TD, Blüher M, Tschöp MH, DiMarchi RD. Anti-obesity drug discovery: advances and challenges. Nat Rev Drug Discov. 2022;21:201-223.
17. Lingvay I, Sumithran P, Cohen RV, le Roux CW. Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet. 2022; 399: 394-405.
18. LiuD,HuangY,HuangC,YangS,WeiX,ZhangP,GuoD,LinJ,XuB,LiC,HeH,HeJ, Liu S, Shi L, Xue Y, Zhang H. Calorie Restriction with or without Time-Restricted Eating in Weight Loss. N Engl J Med. 2022;386: 1495-1504.
19. Slomski A. Adding Time-Restricted Eating to Caloric Restriction for Weight Loss. JAMA. 2022; 327:1950.
20. de Cabo R, Mattson MP. Effects of Intermittent Fasting on Health, Aging, and Disease. N Engl J Med. 2019;381(26):2541-2551.
21. Roman YM, Dominguez MC, Easow TM, Pasupuleti V, White CM, Hernandez AV. Effects of intermittent versus continuous dieting on weight and body composition in obese and overweight people: a systematic review and meta-analysis of randomized controlled trials. Int J Obes (Lond). 2019;43(10):2017-2027.
22. Kaplan A, Zelicha H, Yaskolka Meir A, Rinott E, Tsaban G, Levakov G, Prager O, Salti M, Yovell Y, Ofer J, Huhn S, Beyer F, Witte V, Villringer A, Meiran N, B Emesh T, Kovacs P, von Bergen M, Ceglarek U, Blüher M, Stumvoll M, Hu FB, Stampfer MJ, Friedman A, Shelef I, Avidan G, Shai I. The effect of a high-polyphenol Mediterranean diet (Green-MED) combined with physical activity on age-related brain atrophy: the Dietary Intervention Randomized Controlled Trial Polyphenols Unprocessed Study (DIRECT PLUS). Am J Clin Nutr. 2022; 115: 1270-1281.
23. Shai I, Schwarzfuchs D, Henkin Y, Shahar DR, Witkow S, Greenberg I, Golan R, Fraser D, Bolotin A, Vardi H, Tangi-Rozental O, Zuk-Ramot R, Sarusi B, Brickner D, Schwartz Z, Sheiner E, Marko R, Katorza E, Thiery J, Fiedler GM, Blüher M, Stumvoll M, Stampfer MJ. Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet. Dietary Intervention Randomized Controlled Trial (DIRECT) Group. N Engl J Med. 2008 Jul 17;359(3):229-41.
24. Schwarzfuchs D, Golan R, Shai I. Four-year follow-up after two-year dietary interventions. N Engl J Med. 2012 Oct 4;367(14):1373-4.
25. Aldubayan MA, Pigsborg K, Gormsen SMO, Serra F, Palou M, Galmés S, Palou-March A, Favari C, Wetzels M, Calleja A, Rodríguez Gómez MA, Castellnou mg, Caimari A, Galofré M, Suñol D, Escoté X, Alcaide-Hidalgo JM, M Del Bas J, Gutierrez B, Krarup T, Hjorth MF, Magkos F. A double-blinded, randomized, parallel intervention to evaluate biomarker-based nutrition plans for weight loss: The PREVENTOMICS study. Clin Nutr. 2022;41: 1834-1844.
26. Paisey R, Daniels C, Howitt W, Greatorex D, Campbell C, Paisey C, Paisey R, Frost J, Bromige R. Body weight, diabetes incidence vascular events and survival 15 years after very low calorie diet in community medical clinics in the UK. BMJ Nutr Prev Health. 2022; 5:55-61.
27. Paluch AE, Bajpai S, Bassett DR, Carnethon MR, Ekelund U, Evenson KR, Galuska DA, Jefferis BJ, Kraus WE, Lee IM, Matthews CE, Omura JD, Patel AV, Pieper CF, Rees- Punia E, Dallmeier D, Klenk J, Whincup PH, Dooley EE, Pettee Gabriel K, Palta P, Pompeii LA, Chernofsky A, Larson mg, Vasan RS, Spartano N, Ballin M, Nordström P, Nordström A, Anderssen SA, Hansen BH, Cochrane JA, Dwyer T, Wang J, Ferrucci L, Liu F, Schrack J, Urbanek J, Saint-Maurice PF, Yamamoto N, Yoshitake Y, Newton RL Jr, Yang S, Shiroma EJ, Fulton JE; Steps for Health Collaborative. Daily steps and all- cause mortality: a meta-analysis of 15 international cohorts. Lancet Public Health. 2022;7: e219-e228.
28. LiuZ,GaoP,GaoAY,LinY,FengXX,ZhangF,XuLQ,NiuWY,FangH,ZhouS,LiWH, Yuan JH, Xu CX, Wu N, Li HJ, Wen LM, Patton GC, Wang HJ, Wu YF. Effectiveness of a Multifaceted Intervention for Prevention of Obesity in Primary School Children in China: A Cluster Randomized Clinical Trial. JAMA Pediatr. 2022;176: e214375.
29. Bellicha A, Ciangura C, Roda C, Torcivia A, Aron-Wisnewsky J, Poitou C, Oppert JM. Effect of exercise training after bariatric surgery: A 5-year follow-up study of a randomized controlled trial. PLoS One. 2022;17: e0271561.
30. Fritsche A, Wagner R, Heni M, Kantartzis K, Machann J, Schick F, Lehmann R, Peter A, Dannecker C, Fritsche L, Valenta V, Schick R, Nawroth PP, Kopf S, Pfeiffer AFH, Kabisch S, Dambeck U, Stumvoll M, Blüher M, Birkenfeld AL, Schwarz P, Hauner H, Clavel J, Seißler J, Lechner A, Müssig K, Weber K, Laxy M, Bornstein S, Schürmann A, Roden M, de Angelis MH, Stefan N, Häring HU. Different Effects of Lifestyle Intervention in High- and Low-Risk Prediabetes: Results of the Randomized Controlled Prediabetes Lifestyle Intervention Study (PLIS). Diabetes. 2021 Dec;70(12):2785-2795.
31. Zhu R, Jalo E, Silvestre MP, Poppitt SD, Handjieva-Darlenska T, Handjiev S, Huttunen-Lenz M, Mackintosh K, Stratton G, Navas-Carretero S, Pietiläinen KH, Simpson E, Macdonald IA, Muirhead R, Brand-Miller J, Fogelholm M, Færch K, Martinez JA, Westerterp-Plantenga MS, Adam TC, Raben A. Does the Effect of a 3-Year Lifestyle Intervention on Body Weight and Cardiometabolic Health Differ by Prediabetes Metabolic Phenotype? A Post Hoc Analysis of the PREVIEW Study. Diabetes Care. 2022 Jun 13:dc220549.
32. Bundesinsitut für Arzneimittel und Medizinprodukte. Finden Sie die passende digitale Gesundheitsanwendung. https://diga.bfarm.de/de letzter Zugriff am 25.07.2022.
33. Katula JA, Dressler EV, Kittel CA, Harvin LN, Almeida FA, Wilson KE, Michaud TL, Porter GC, Brito FA, Goessl CL, Jasik CB, Sweet CMC, Schwab R, Estabrooks PA. Effects of a Digital Diabetes Prevention Program: An RCT. Am J Prev Med. 2022; 62: 567-577.
34. ShiQ,WangY,HaoQ,VandvikPO,GuyattG,LiJ,ChenZ,XuS,ShenY,GeL,SunF,Li L, Yu J, Nong K, Zou X, Zhu S, Wang C, Zhang S, Qiao Z, Jian Z, Li Y, Zhang X, Chen K, Qu F, Wu Y, He Y, Tian H, Li S. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials. Lancet. 2022;399:259-269.
35. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384: 989.
36. Alabduljabbar K, Al-Najim W, le Roux CW. The Impact Once-Weekly Semaglutide 2.4 mg Will Have on Clinical Practice: A Focus on the STEP Trials. Nutrients. 2022;14: 2217.
37. Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, Rosenstock J, Shimomura I, Viljoen A, Wadden TA, Lingvay I, STEP 2 Study Group Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet 2021 Mar 13;397(10278):971-984.
38. Kushner RF, Calanna S, Davies M, et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity (Silver Spring). 2020;28: 1050-1061.
39. Ryan DH, Lingvay I, Colhoun HM, Deanfield J, Emerson SS, Kahn SE, Kushner RF, Marso S, Plutzky J, Brown-Frandsen K, Gronning MOL, Hovingh GK, Holst AG, Ravn H, Lincoff AM. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Am Heart J. 2020 Nov;229:61-69.
40. Perreault L, Davies M, Frias JP, Laursen PN, Lingvay I, Machineni S, Varbo A, Wilding JPH, Wallenstein SOR, le Roux CW. Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. Diabetes Care. 2022 Jun 20:dc211785.
41. Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, Lingvay I, McGowan BM, Oral TK, Rosenstock J, Wadden TA, Wharton S, Yokote K, Kushner RF; STEP 1 Study Group. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes Obes Metab. 2022; 24: 1553-1564.
42. Kadowaki T, Isendahl J, Khalid U, Lee SY, Nishida T, Ogawa W, Tobe K, Yamauchi T, Lim S; STEP 6 investigators. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial. Lancet Diabetes Endocrinol. 2022; 10:193-206.
43. Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022; 387: 205-216.
44. Sattar N, McGuire DK, Pavo I, Weerakkody GJ, Nishiyama H, Wiese RJ, Zoungas S. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022 Mar;28(3):591-598.
45. Enebo LB, Berthelsen KK, Kankam M, Lund MT, Rubino DM, Satylganova A, Lau DCW. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021 May 8;397(10286):1736-1748.
46. Abu Dayyeh BK, Maselli DB, Rapaka B, Lavin T, Noar M, Hussan H, Chapman CG, Popov V, Jirapinyo P, Acosta A, Vargas EJ, Storm AC, Bazerbachi F, Ryou M, French M, Noria S, Molina D, Thompson CC. Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial. Lancet. 2021;398: 1965-1973.
47. Mocanu V, Zhang Z, Deehan EC, Kao DH, Hotte N, Karmali S, Birch DW, Samarasinghe KK, Walter J, Madsen KL. Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial. Nat Med. 2021; 27: 1272-1279.
48. Aminian A, Wilson R, Al-Kurd A, Tu C, Milinovich A, Kroh M, Rosenthal RJ, Brethauer SA, Schauer PR, Kattan MW, Brown JC, Berger NA, Abraham J, Nissen SE. Association of Bariatric Surgery With Cancer Risk and Mortality in Adults With Obesity. JAMA. 2022 Jun 28;327(24):2423-2433.
49. Lange UG, Moulla Y, Schütz T, Blüher M, Peter V, Shang E, Dietrich A. Effectiveness and Tolerability of a Two-Week Hypocaloric Protein-Rich Diet Prior to Obesity Surgery with Two Different Diet Interventions: a Prospective Randomized Trial. Obes Surg. 2022 Jul 18. doi: 10.1007/s11695-022-06180-z.
50. Murphy R, Plank LD, Clarke mg, Evennett NJ, Tan J, Kim DDW, Cutfield R, Booth MWC. Effect of Banded Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy on Diabetes Remission at 5 Years Among Patients With Obesity and Type 2 Diabetes: A Blinded Randomized Clinical Trial. Diabetes Care. 2022; 45: 1503-1511.

C) Lipide

1. Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337. https://doi.org/10.1093/eurheartj/ehab484
2. Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2019. https://doi.org/10.1093/eurheartj/ehz455
3. Kim JE, Park S, Kim MS, et al. Statin initiation and all-cause mortality in incident statin-naïve dialysis patients. Atherosclerosis. 2021;337:59-65. https://doi.org/10.1016/j.atherosclerosis.2021.08.026
4. Kim J, Nishimura Y, Kewcharoen J, Yess J. Statin Use Can Attenuate the Decline in Left Ventricular Ejection Fraction and the Incidence of Cardiomyopathy in Cardiotoxic Chemotherapy Recipients: A Systematic Review and Meta-Analysis. J Clin Med. 2021;10(16). https://doi.org/10.3390/jcm10163731
5. De Giorgi R, Rizzo Pesci N, Quinton A, De Crescenzo F, Cowen PJ, Harmer CJ. Statins in Depression: An Evidence-Based Overview of Mechanisms and Clinical Studies. Front Psychiatry. 2021;12:702617. https://doi.org/10.3389/fpsyt.2021.702617
6. Vallejo-Vaz AJ, Packard CJ, Ference BA, et al. LDL-cholesterol lowering and clinical outcomes in hypercholesterolemic subjects with and without a familial hypercholesterolemia phenotype: Analysis from the secondary prevention 4S trial. Atherosclerosis. 2021;320:1-9. https://doi.org/10.1016/j.atherosclerosis.2021.01.003
7. van Rosendael AR, van den Hoogen IJ, Gianni U, et al. Association of Statin Treatment With Progression of Coronary Atherosclerotic Plaque Composition. JAMA Cardiology. 2021;6(11):1257-66. https://doi.org/10.1001/jamacardio.2021.3055
8. Kohli-Lynch CN, Bellows BK, Zhang Y, et al. Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults. J Am Coll Cardiol. 2021;78(20):1954-64. https://doi.org/10.1016/j.jacc.2021.08.065
9. Vahedian-Azimi A, Bianconi V, Makvandi S, et al. A systematic review and meta-analysis on the effects of statins on pregnancy outcomes. Atherosclerosis. 2021;336:1-11. https://doi.org/10.1016/j.atherosclerosis.2021.09.010
10. Howard JP, Wood FA, Finegold JA, et al. Side Effect Patterns in a Crossover Trial of Statin, Placebo, and No Treatment. J Am Coll Cardiol. 2021;78(12):1210-22. https://doi.org/10.1016/j.jacc.2021.07.022
11. Lee SA, Kim W, Hong TJ, et al. Effects of Fixed-dose Combination of Low-intensity Rosuvastatin and Ezetimibe Versus Moderate-intensity Rosuvastatin Monotherapy on Lipid Profiles in Patients With Hypercholesterolemia: A Randomized, Double-blind, Multicenter, Phase III Study. Clin Ther. 2021;43(9):1573-89. https://doi.org/10.1016/j.clinthera.2021.07.016
12. Blaum C, Brunner FJ, Goßling A, et al. Target Populations and Treatment Cost for Bempedoic Acid and PCSK9 Inhibitors: A Simulation Study in a Contemporary CAD Cohort. Clin Ther. 2021;43(9):1583-600. https://doi.org/10.1016/j.clinthera.2021.07.019
13. Lepor NE, Sun J, Canton G, et al. Regression in carotid plaque lipid content and neovasculature with PCSK9 inhibition: A time course study. Atherosclerosis. 2021;327:31-8. https://doi.org/10.1016/j.atherosclerosis.2021.05.008
14. Lorenzatti AJ, Monsalvo ML, López JAG, Wang H, Rosenson RS. Effects of evolocumab in individuals with type 2 diabetes with and without atherogenic dyslipidemia: An analysis from BANTING and BERSON. Cardiovasc Diabetol. 2021;20(1):94. https://doi.org/10.1186/s12933-021-01287-6
15. Sammour Y, Dezorzi C, Austin BA, et al. PCSK9 Inhibitors in Heart Transplant Patients: Safety, Efficacy, and Angiographic Correlates. J Card Fail. 2021;27(7):812-5. https://doi.org/10.1016/j.cardfail.2021.02.018
16. Landmesser U, Haghikia A, Leiter LA, et al. Effect of inclisiran, the small-interfering RNA against proprotein convertase subtilisin/kexin type 9, on platelets, immune cells, and immunological biomarkers: a pre-specified analysis from ORION-1. Cardiovasc Res. 2021;117(1):284-91. https://doi.org/10.1093/cvr/cvaa077
17. Reeskamp LF, Nurmohamed NS, Bom MJ, et al. Marked plaque regression in homozygous familial hypercholesterolemia. Atherosclerosis. 2021;327:13-7. https://doi.org/10.1016/j.atherosclerosis.2021.04.014
18. Jo SH, Nam H, Lee J, Park S, Lee J, Kyoung DS. Fenofibrate Use Is Associated With Lower Mortality and Fewer Cardiovascular Events in Patients With Diabetes: Results of 10,114 Patients From the Korean National Health Insurance Service Cohort. Diabetes Care. 2021;44(8):1868-76. https://doi.org/10.2337/dc20-1533
19. Ray KK, Molemans B, Schoonen WM, et al. EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279-89. https://doi.org/10.1093/eurjpc/zwaa047
20. Vahedian-Azimi A, Mohammadi SM, Heidari Beni F, et al. Improved COVID-19 ICU admission and mortality outcomes following treatment with statins: a systematic review and meta- analysis. Archives of medical science : AMS. 2021;17(3):579-95. https://doi.org/110.5114/aoms/132950
21. Vladimirova-Kitova L, Kitov S, Ganev M, Chochkova-Bukova L. Case Report: Difficulties in the Treatment of a 12-Year-Old Patient With Homozygous Familial Hypercholesterolemia, Compound Heterozygous Form - 5 Years Follow-Up. Frontiers in cardiovascular medicine. 2021;8:743341. https://doi.org/10.3389/fcvm.2021.743341
22. Yeung J, Chisholm K, Spinks C, Srinivasan S. Familial hypercholesterolaemia: Experience of a tertiary paediatric lipid clinic. J Paediatr Child Health. 2021;57(8):1201-7. https://doi.org/10.1111/jpc.15426
23. Gitsels LA, Bakbergenuly I, Steel N, Kulinskaya E. Do statins reduce mortality in older people? Findings from a longitudinal study using primary care records. Fam Med Community Health. 2021;9(2). https://doi.org/10.1136/fmch-2020-000780
24. Hess CN, Cannon CP, Beckman JA, et al. Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. J Am Coll Cardiol. 2021;77(24):3016-27. https://doi.org/10.1016/j.jacc.2021.04.060
25. Sofat S, Chen X, Chowdhury MM, Coughlin PA. Effects of Statin Therapy and Dose on Cardiovascular and Limb Outcomes in Peripheral Arterial Disease: A Systematic Review and Meta-analysis. Eur J Vasc Endovasc Surg. 2021;62(3):450-61. https://doi.org/10.1016/j.ejvs.2021.05.025
26. Kanda D, Miyata M, Ikeda Y, et al. The Priority of Non-HDL-C Assessment to Predict New Lesions among Stable Angina Patients with Strong Statins. J Atheroscler Thromb. 2022;29(6):894-905. https://doi.org/10.5551/jat.62908

1. Reincke M, Bancos I, Mulatero P, Scholl UI, Stowasser M, Williams TA Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol 2021; 9:876-892.
2. Hundemer GL, Imsirovic H, Vaidya A, Yozamp N, Goupil R, Madore F, Agharazii M, Knoll G, Sood MM Screening Rates for Primary Aldosteronism Among Individuals With Hypertension Plus Hypokalemia: A Population-Based Retrospective Cohort Study. Hypertension 2022; 79:178-186.
3. Rossi GP , Ceolotto G, Rossitto G, Maiolino G, Cesari M, Seccia TM Effects of Mineralocorticoid and AT1 Receptor Antagonism on The Aldosterone-Renin Ratio In Primary Aldosteronism-the EMIRA Study. J Clin Endocrinol Metab 2020; 105. https://doi.org/10.1210/clinem/dgaa080
4. Pecori A, Buffolo F, Burrello J, Mengozzi G, Rumbolo F, Avataneo V, D'Avolio A, Rabbia F, Bertello C, Veglio F, Mulatero P, Monticone S Mineralocorticoid Receptor Antagonist Effect on Aldosterone to Renin Ratio in Patients With Primary Aldosteronism. J Clin Endocrinol Metab 2021; 106:e3655-e3664.
5. Eisenhofer G, Kurlbaum M, Peitzsch M, Constantinescu G, Remde H, Schulze M, Kaden D, Muller LM, Fuss CT, Kunz S, Kolodziejczyk-Kruk S, Gruber S, Prejbisz A, Beuschlein F, Williams TA, Reincke M, Lenders JWM, Bidlingmaier M 2022 The saline infusion test for primary aldosteronism: implications of immunoassay inaccuracy. J Clin Endocrinol Metab:epub 2021/2012/2029. https://doi.org/10.1210/clinem/dgab924
6. Rossi GP, Crimi F, Rossitto G, Amar L, Azizi M, Riester A, Reincke M, Degenhart C, Widimsky J, Naruse M, Deinum J, Schultze Kool L, Kocjan T, Negro A, Rossi E, Kline G, Tanabe A, Satoh F, Christian Rump L, Vonend O, Willenberg HS, Fuller PJ, Yang J, Chee NYN, Magill SB, Shafigullina Z, Quinkler M, Oliveras A, Cent Wu V, Kratka Z, Barbiero G, Seccia TM, Battistel M. Identification of Surgically Curable Primary Aldosteronism by Imaging in a Large, Multiethnic International Study. J Clin Endocrinol Metab 2021; 106:e4340-e4349.
7. Rossi GP, Crimi F, Rossitto G, Amar L, Azizi M, Riester A, Reincke M, Degenhart C, Widimsky J, Naruse M, Deinum J, Kool LS, Kocjan T, Negro A, Rossi E, Kline G, Tanabe A, Satoh F, Rump LC, Vonend O, Willenberg HS, Fuller PJ, Yang J, Chee NYN, Magill SB, Shafigullina Z, Quinkler M, Oliveras A, Wu VC, Kratka Z, Barbiero G, Battistel M, Seccia TM. Feasibility of Imaging-Guided Adrenalectomy in Young Patients With Primary Aldosteronism. Hypertension 2022; 79:187-195.
8. Gkaniatsa E, Sakinis A, Palmer M, Muth A, Trimpou P, Ragnarsson O. Adrenal Venous Sampling in Young Patients with Primary Aldosteronism. Extravagance or Irreplaceable? J Clin Endocrinol Metab 2021; 106:e2087-e2095.
9. Fuss CT, Brohm K, Fassnacht M, Kroiss M, Hahner S. Reassessment of Postural Stimulation Testing as a Simple Tool to Identify a Subgroup of Patients With Unilateral Primary Aldosteronism. J Clin Endocrinol Metab 2022; 107:e865-e873.
10. Wu VC, Wang SM, Huang KH, Tsai YC, Chan CK, Yang SY, Lin LY, Chang CC, Lu CC, Lin YH, Chen YM, Chueh JS. Long-term mortality and cardiovascular events in patients with unilateral primary aldosteronism after targeted treatments. Eur J Endocrinol 2021; 186:195-205.
11. Kohler A, Sarkis AL, Heinrich DA, Muller L, Handgriff L, Deniz S, Schneider H, Kunzel H, Ladurner R, Reincke M, Adolf C. Renin, a marker for left ventricular hypertrophy, in primary aldosteronism: a cohort study. Eur J Endocrinol 2021; 185:663-672.
12. Puar TH, Cheong CK, Foo RSY, Saffari SE, Tu TM, Chee MR, Zhang M, Ng KS, Wong KM, Wong A, Ng FC, Aw TC, Khoo J, Gani L, King T, Loh WJ, Soh SB, Au V, Tay TL, Tan E, Mae L, Yew J, Tan YK, Tong KL, Lee S, Chai SC. Treatment of Primary Aldosteronism and Reversal of Renin Suppression Improves Left Ventricular Systolic Function. Front Endocrinol (Lausanne) 2022; 13:916744.
13. Reincke M, Williams TA. True unilateral primary aldosteronism exists, and unilateral adrenalectomy saves lives. Eur J Endocrinol 2022; 186:C5-C7.
14 Funder JW, Carey RM. Primary Aldosteronism: Where Are We Now? Where to From Here? Hypertension 2022; 79:726-735. 17. 18.
15. Ebbehoj A, Li D, Kaur RJ, Zhang C, Singh S, Li T, Atkinson E, Achenbach S, Khosla S, Arlt W, Young WF, Rocca WA, Bancos I. Epidemiology of adrenal tumours in Olmsted County, Minnesota, USA: a population-based cohort study. Lancet Diabetes Endocrinol 2020; 8:894- 902.
16. Fassnacht M, Arlt W, Bancos I, Dralle H, Newell-Price J, Sahdev A, Tabarin A, Terzolo M, Tsagarakis S, Dekkers OM. Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 2016; 175:G1-G34.
17. Remde H, Kimpel O, Fassnacht M. [Adrenal incidentaloma - differential diagnosis and management]. Dtsch Med Wochenschr 2022; 147:85-91.
18. Bancos I, Taylor AE, Chortis V, Sitch AJ, Jenkinson C, Davidge-Pitts CJ, Lang K, Tsagarakis S, Macech M, Riester A, Deutschbein T, Pupovac ID, Kienitz T, Prete A, Papathomas TG, Gilligan LC, Bancos C, Reimondo G, Haissaguerre M, Marina L, Grytaas MA, Sajwani A, Langton K, Ivison HE, Shackleton CHL, Erickson D, Asia M, Palimeri S, Kondracka A, Spyroglou A, Ronchi CL, Simunov B, Delivanis DA, Sutcliffe RP, Tsirou I, Bednarczuk T, Reincke M, Burger-Stritt S, Feelders RA, Canu L, Haak HR, Eisenhofer G, Dennedy MC, Ueland GA, Ivovic M, Tabarin A, Terzolo M, Quinkler M, Kastelan D, Fassnacht M, Beuschlein F, Ambroziak U, Vassiliadi DA, O'Reilly MW, Young WF, Jr., Biehl M, Deeks JJ, Arlt W, Investigators EE-A. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes Endocrinol 2020; 8:773-781.
19. Schloetelburg W, Ebert I, Petritsch B, Weng AM, Dischinger U, Kircher S, Buck AK, Bley TA, Deutschbein T, Fassnacht M. Adrenal wash-out CT: moderate diagnostic value in distinguishing benign from malignant adrenal masses. Eur J Endocrinol 2021; 186:183-193.
20. Sundin A; Commentary on Adrenal wash-out CT: moderate diagnostic value in distinguishing benign from malignant masses. Eur J Endocrinol 2022; 186:C9-C12.
21. Prete A, Subramanian A, Bancos I, Chortis V, Tsagarakis S, Lang K, Macech M, Delivanis DA, Pupovac ID, Reimondo G, Marina LV, Deutschbein T, Balomenaki M, O'Reilly MW, Gilligan LC, Jenkinson C, Bednarczuk T , Zhang CD, Dusek T , Diamantopoulos A, Asia M, Kondracka A, Li D, Masjkur JR, Quinkler M, Ueland GA, Dennedy MC, Beuschlein F, Tabarin A, Fassnacht M, Ivovic M, Terzolo M, Kastelan D, Young WF, Jr., Manolopoulos KN, Ambroziak U, Vassiliadi DA, Taylor AE, Sitch AJ, Nirantharakumar K, Arlt W, Investigators* EE-A, Investigators EE-A. Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors : A Cross-Sectional Multicenter Study. Ann Intern Med 2022; 175:325-334.
22. Kjellbom A, Lindgren O, Puvaneswaralingam S, Londahl M, Olsen H. Association Between Mortality and Levels of Autonomous Cortisol Secretion by Adrenal Incidentalomas : A Cohort Study. Ann Intern Med 2021; 174:1041-1049.
23. Deutschbein T, Reimondo G, Di Dalmazi G, Bancos I, Patrova J, Vassiliadi DA, Nekic AB, Debono M, Lardo P, Ceccato F, Petramala L, Prete A, Chiodini I, Ivovic M, Pazaitou- Panayiotou K, Alexandraki KI, Hanzu FA, Loli P, Yener S, Langton K, Spyroglou A, Kocjan T, Zacharieva S, Valdes N, Ambroziak U, Suzuki M, Detomas M, Puglisi S, Tucci L, Delivanis DA, Margaritopoulos D, Dusek T, Maggio R, Scaroni C, Concistre A, Ronchi CL, Altieri B, Mosconi C, Diamantopoulos A, Iniguez-Ariza NM, Vicennati V, Pia A, Kroiss M, Kaltsas G, Chrisoulidou A, Marina LV, Morelli V, Arlt W, Letizia C, Boscaro M, Stigliano A, Kastelan D, Tsagarakis S, Athimulam S, Pagotto U, Maeder U, Falhammar H, Newell-Price J, Terzolo M, Fassnacht M. Age-dependent and sex- dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes Endocrinol 2022; 10:499-508.
24. Pofi R, Tomlinson JW. Is autonomous cortisol secretion sexually dimorphic? Lancet Diabetes Endocrinol 2022; 10:473-475.
25. Vogg N, Kurlbaum M, Deutschbein T, Grasl B, Fassnacht M, Kroiss M. Method-Specific Cortisol and Dexamethasone Thresholds Increase Clinical Specificity of the Dexamethasone Suppression Test for Cushing Syndrome. Clinical chemistry 2021; 67:998-1007.
26. Liu MS, Lou Y, Chen H, Wang YJ, Zhang ZW, Li P, Zhu DL. Performance of DHEAS as a Screening Test for Autonomous Cortisol Secretion in Adrenal Incidentalomas: A Prospective Study. J Clin Endocrinol Metab 2022; 107:e1789-e1796.
27. Olmos R, Mertens N, Vaidya A, Uslar T, Fernandez P, Guarda FJ, Zuniga A, San Francisco I, Huete A, Baudrand R. Discriminative Capacity of CT Volumetry to Identify Autonomous Cortisol Secretion in Incidental Adrenal Adenomas. J Clin Endocrinol Metab 2022; 107:e1946-e1953.
28. Nolting S, Bechmann N, Taieb D, Beuschlein F, Fassnacht M, Kroiss M, Eisenhofer G, Grossman A, Pacak K. Personalized Management of Pheochromocytoma and Paraganglioma. Endocr Rev 2022; 43:199-239.
29. Remde H, Nolting S. [Pheochromocytoma - Disease Model for Personalized Medicine]. Dtsch Med Wochenschr 2021;146:1520-1526.
30. Horton C, LaDuca H, Deckman A, Durda K, Jackson M, Richardson ME, Tian Y, Yussuf A, Jasperson K, Else T . Universal Germline Panel Testing for Individuals With Pheochromocytoma and Paraganglioma Produces High Diagnostic Yield. J Clin Endocrinol Metab 2022; 107:e1917-e1923.
31. ZhangJ,LiM,PangY,WangC,WuJ,ChengZ,LiX,LuZ,LiuY,GuoJ,ChenX,HeY, Guan X, Xu X, Wang Y, Liu J, Guo W, Hou Y, Liu L, Jiang J, Gao X. Genetic Characteristics of Incidental Pheochromocytoma and Paraganglioma. J Clin Endocrinol Metab 2022; 107:e1835-e1842.
32. Amar L, Pacak K, Steichen O, Akker SA, Aylwin SJB, Baudin E, Buffet A, Burnichon N, Clifton-Bligh RJ, Dahia PLM, Fassnacht M, Grossman AB, Herman P, Hicks RJ, Januszewicz A, Jimenez C, Kunst HPM, Lewis D, Mannelli M, Naruse M, Robledo M, Taieb D, Taylor DR, Timmers H, Treglia G, Tufton N, Young WF, Lenders JWM, Gimenez-Roqueplo AP , Lussey-Lepoutre C International consensus on initial screening and follow-up of asymptomatic SDHx mutation carriers. Nat Rev Endocrinol 2021; 17:435-444.
33. Davidoff DF, Benn DE, Field M, Crook A, Robinson BG, Tucker K, De Abreu Lourenco R, Burgess JR, Clifton-Bligh RJ. Surveillance Improves Outcomes for Carriers of SDHB Pathogenic Variants: A Multicenter Study. J Clin Endocrinol Metab 2022; 107:e1907-e1916.
34. Lenders JWM, Kerstens MN, Amar L, Prejbisz A, Robledo M, Taieb D, Pacak K, Crona J, Zelinka T, Mannelli M, Deutschbein T, Timmers H, Castinetti F, Dralle H, Widimsky J, Gimenez-Roqueplo AP , Eisenhofer G. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens 2020; 38:1443-1456.
35. Remde H, Pamporaki C, Quinkler M, Nolting S, Prejbisz A, Timmers H, Masjkur J, Fuss CT, Fassnacht M, Eisenhofer G, Deutschbein T 2022 Improved Diagnostic Accuracy of Clonidine Suppression Testing Using an Age-Related Cutoff for Plasma Normetanephrine. Hypertension 79:1257-1264.
36. Tsiomidou S, Pamporaki C, Geroula A, Van Baal L, Weber F, Dralle H, Schmid KW, Fuhrer D, Unger N. Clonidine suppression test for a reliable diagnosis of pheochromocytoma: When to use. Clin Endocrinol (Oxf) 2022 Mar 11. https://doi.org/10.1210/clinem/dgab924
37. Lenders JW, Duh QY, Eisenhofer G, Gimenez-Roqueplo AP, Grebe SK, Murad MH, Naruse M, Pacak K, Young WF, Jr. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99:1915-1942.
38. Castinetti F, De Freminville JB, Guerin C, Cornu E, Sarlon G, Amar L. Controversies about the systematic preoperative pharmacological treatment before pheochromocytoma or paraganglioma surgery. Eur J Endocrinol 2022; 186:D17-D24.
39. Groeben H, Walz MK, Nottebaum BJ, Alesina PF, Greenwald A, Schumann R, Hollmann MW, Schwarte L, Behrends M, Rossel T, Groeben C, Schafer M, Lowery A, Hirata N, Yamakage M, Miller JA, Cherry TJ, Nelson A, Solorzano CC, Gigliotti B, Wang TS, Wietasch JKG, Friederich P, Sheppard B, Graham PH, Weingarten TN, Sprung J. International multicentre review of perioperative management and outcome for catecholamine-producing tumours. Br J Surg 2020; 107:e170-e178.
40. Jaiswal SK, Memon SS, Lila A, Sarathi V, Goroshi M, Garg R, Barnabas R, Hemantkumar I, Patel RD, Oak S, Dalvi A, Garale M, Patil V, Shah NS, Bandgar T. Preoperative Amlodipine Is Efficacious in Preventing Intraoperative HDI in Pheochromocytoma: Pilot RCT. J Clin Endocrinol Metab 2021; 106:e2907-e2918.

1. Georgakopoulou VE, Avramopoulos P, Papalexis P, Bitsani A, Damaskos C, Garmpi A, Venetikou MS, Paramythiotis D, Karlafti E, Sklapani P, Trakas N, Spandidos DA. COVID-19 induced hypoparathyroidism: A case report. Experimental and Therapeutic Medicine 2022;23: 346. https://doi.org/10.3892/etm.2022.11276 Epub 2022 Mar 23.
2. Pal R, Bhadada SK, Mikherjee S, Banerjee M, Kumar R. Fracture risk in hypoparathyroididsm: a systematic review and meta-analysis. Osteoporos Int 2021;32:2145-2153
3. Saha S, Mannar V, Kandasamy D, Sreenivas V, Goswami R. Vertebral fractures, trabecular bone score and their determinants in chronic hypoparathyroidism. J Endocrinol Invest 2022; May 19. https://doi.org/10.1007/s40618-022-01818-2 Online ahead of print
4. Swartling O, Evans M, Spelman T, Kamal W, Kämpe O, Mannstadt M, Lagerros YT, Björnsdottir S. Kidney Complications and Hospitalization in Patients with Chronic Hypoparathyroidism: A Cohort Study in Sweden. J Clin Endocrinol Metab 2022;Jul 30;dgac456. https://doi.org/10.1210/clinem/dgac456
5. Polonine S, de Santa Rosa RG, Farias MLF, Garcia MI, Gomes CP, Gottlieb I, Madeira M Hyperphosphatemia is associated with cardiac valve calcification in chronic hypoparathyroidism. J Endocrinol Invest 2022; 45:1359-1366
6. Brescia MDG, Rodrigues KC, d ́Alessandro AF, Filho WA, van der Plas WY, Kruijff S, Arap SS, Toledo SPA, de Menezes Montenegro FL, Lourenco DM. Impact of parathyreoidectomy on quality of life in multiple endocrine neoplasia type 1. Endocrine Connections 2022;11:e220021
7. Frey S, Figueres L, Pattou F, Le Bras M, Caillard C, Mathonnet M, Hamy A, Brunaud L, Lifante JC, Trésallet C, Sebag F, Menegaux F, Blanchard C, Leroy M, Mirallié E, Qol-HypoparaStudy Group. Impact of Permanent Post-thyroidectomy Hypoparathyroidism on Self-evalutation of Quality of Life and Voice: Results From the National QoL-Hypopara Study. Ann Surg 2021;274:851-858
8. Saponaro F, Alfi G, Cetani F, Matrone A, Mazoni L, Apicella M, Pardi E, Borsari S, Laurino M, Lai E, Gemignani A, Marcocci C. Serum calcium levels are associated with cognitive function in hypoparathyroidism: a neuropsychological and biochemical study in an Italian cohort of patients with chronic post-surgical hypoparathyroidism. J Endocrinol Invest 2022; Jun 25. https://doi.org/10.1007/s40618-022-01822-6 Online ahead of print
9. Anaforoglu I, Sancak S, Akbas EM, Oruk GG, Canat M, Tezcan KA, Uc ZA, Gorar S, Duman GC, Yaylali GF, Yilmaz M, Bilir BE, Bozoglan H, Akbaba G, Tuna MM, Akcay S, Tuzhun D, Bagir GS, Haydardedeoglu FE; Elbuken G, Yorulmaz G, Celic O, Topbas M. Effects of Treatment Adherence on Quality of Life in Hypoparathyroid Patients. Exp Clin Endocrinol Diabetes 2021;129:918-925
10. Büttner M, Krogh D, Siggelkow H, Singer S. What are predictors of impaired quality of life patients with hypoparathyroidism? . clinical Endocrinology 2022;97:268-275
11. Stamm B, Blaschke M, Wilken L, Wilde D, Heppner C, Leha A, Herrmann-Lingen C, Siggelkow H. The Influence of Conventional Treatment on Symptoms and Complaints in Patients With Chronic Postsurgical Hypoparathyroidism JBMR® Plus (WOA), Vol. 6, No. 2, February 2022, e10586. DOI: 10.1002/jbm4.10586 https://doi.org/10.1002/jbm4.10586
12. Guglielmetti L, Schmidt S, Busch M, Wagner J, Naddaf A, Leitner B, Harsch S, Zielke A, Smaxwil C. How Long Does It Take to Regain Normocalcaemia in the Event of Postsurgical Hypoparathyroidism? A Detailed Time Course Analysis. Journal of Clinical Medicine 2022;11:3202 https://doi.org/10.3390/jcm11113202 https://doi.org/10.3390/jcm11113202
13. Paladino NC, Guérin C, Graziani J, Morange I, Loundou A, Taieb D, Sebag F. Predicting risk factors of postoperative hypocalcemia after total thyreoidectomy: is safe discharge without supplementation possible? A large cohort study. Langenbecks Arch Surg 2021;406:2425- 2431
14. Riordan F, Brophy C, Murphy MS, Sheahan P. Predictive value of postoperative day 1 parathyroid hormone levels for early and late hypocalcaemia after thyroidectomy. Langenbeck ́s Archives of Surgery 2022;407:1653-1658
15. Canu GL, Medas F, Cappellacci F, Soddu C, Romano G, Erdas E, Calo PG. Intact parathyreoid hormne value on the first postoperative day following total thyreoidectomie as a predictor of permanent hypoparathyreoidism: a retrospective analysis on 426 consecutive patients. Endokrynol Pol 2022;73:49-55
16. Huang T , Zhong X, He T , Zhang W, He Z. Establishing a predictive model of hypoparathyroidism after total thyroidectomy and central lymph node dissection for postoperative calcium supplementation selectively. Ann Transl Med 2022;10(12):678 | https://dx.doi.org/10.21037/atm-22-1779 https://doi.org/10.21037/atm-22-1779
17. Arshad MF , Dhami A, Quarrell G, Balasubramanian SP . Parathyroid hormone of ≥ 1.6 pmol/lat 6 months is associated with recovery in ́long-term ́post-surgical hypoparathyroidism. European Thyroid Journal 2022; May 11;11(3):e210130. doi: 10.1530/ETJ-21-0130 https://doi.org/10.1530/ETJ-21-0130
18. Pereira C, Varghese B. VitaminD3 Levels in Predicting Transient Hypocalcemia After Parathyroidectomy. Cureus 14(7): e26576.DOI 10.7759/cureus.26576
19. Li Z, Fei Y, Li Z, Wei T, Jingqiang Z, Anping S. Outcome of parathyroid function after total thyroidectomy when calcium supplementation is administered routinely versus exclusively to symptomatic patients: A prospective randomized clinical trial. Endocrine 2022;75;583-592
20. Khatiwada AS, Harris AS. Use of pre-operative calcium and Vitamin D supplementation to prevent post-operative hypocalcaemia in patients undergoing thyroidectomy: a systematic review. J Laryngol Otol 2021; 135:568-573
21. Saibene AM, Rosso C, Felisati G, Pipolo C, De Leo S, Lozza P, Cozzolino MG, De Pasquale L. Can preoperative 25-hydroxyVitamin D levels predict transient hypocalcemia after total thyreoidectomy? Updates in Surgery 2022;74:309-316
22. Zhang Y, Zheng W, Huang Y, Chen C. Vitamin D Insufficiency Predicts Susceptibility of Parathyroid Hormone Reduction after Total Thyreoidectomie in Thyroid Cancer Patients. International Journal of Endocrinology 2021; Volume 2021, Article ID 8657918, 7 pages https://doi.org/10.1155/2021/8657918
23. Aouchiche K, Reynaud R, Amodru V, Brue T, Cuny T. Teriparatide administration by the Omnipod pump: preliminary experience from two cases with refractory hypoparathyreoidismö Endocrine 2022;76:179-188
24. Shulman D. Subcutaneous Infusion of rhPTH1-34 During Pregnancy and Nursing in a Women With Autosomal Dominant Hypoparathyroidism 1. Journal of the Endocrine Society 2022;6:1- 5
25. Naciu AM, Tabacco G, Bilezikian JP, Santonati A, Bosco D, Incognito GG, Gaspa G, Manfrini S, Falchett A, Trimboli P, Mazziotti G, Napoli N, Sanson G, Cesareo R, Vescini F, Palermo A. Calcium Citrate Versus Calcium Carbonate in the Management of Chronic Hypoparathyroidism: A Randomized, Double-Blind, Crossover Clinical Trial. Journal of Bone and Mineral Research 2022;37:1251-1259
26. Saha S, Sreenivas V, Goswami R. Alfacalcidol vs Calcitriol in the Management of Patient with Hypoparathyroidism: A Randomized Controlled Trial. J Clin Endocrinol Metab 2021;106:2092-2102
27. Ayodele O, Mu F, Berman R, Swallow E, Rejnmark L, Gosmanova EO, Kaul S. Lower Risk of cardiovascular Events in Adult Patients with Chronic Hypoparathyreoidism Treated with rhPTH(1-84): A Retrosprective Cohort Study. Adv Ther 2022;39:3845-3856
28. Puliani G, Hasenmajer V, Simonelli I, Sada V, Pofi R, Minnetti M, Cozzolino A, Napoli N, Pasqualetti P, Gianfrilli D, Isidori AM. Safety and Efficacy of PTH 1-34 and 1-84 Therapy in Chronic Hypoparathyreoidism. A Meta-Analysis of Prospective Trials. Journal of Bone and Mineral Research 2022;37:1233-1250
29. Roszko KL, Hu TY, Guthrie LC, Brillante BA, Smith M Collins MT, Gafni RI. PTH 1-34 Replacement Therapy Has Minimal Effect on Quality of Life in Patients With Hypoparathyroidism. J of Bone Mineral Res 2022;37:68-77
30. Ruan S, Yang G, Dong Y, Shangguan W, Lu W. Discovery of a Long-Acting Parathyroid Hormone 1-34 Analogue to Treat Hypoparathyroidism. Mol Pham 2021;18:3260-3271
31. Khan AA, Rejnmark L, Rubin M, Schwarz P, Vokes T, Clarke B, Ahmed I, Hofbauer L, Marcocci C, Pagotto U, Palermo A, Eriksen E, Brod M, Markova D, Smith A, Pihl S, Mourya S, Karpf DB, Shu AD. PaTH Forward: A Randomized, Doubl-Blind, Placebo- Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism. J Clin Endocrinol Metab 2022;107:e372-e385
32. Ish-Shalom S Caraco Y, Khazen NS, Gershinsky M, Szalat A, Schwartz P, Arbit E, Galitzer H, Tang JCY, Burshtein G, Rothner A, Raskin A, Blum M, Fraser WD. Safety and Efficacy of Oral Human Parathyroid Hormone (1-34) in Hypoparathyroidism: An Open-Label Study. Journal of Bone and Mineral Research 2021;36:1060-1068
33. Bollerslev J, Rejnmark L, Zahn A, Heck A, Appelman-Dijkstra NM, Cardoso L, Hannan FM, Cetani F, Sikjaer T, Formenti AM, Björnsdottier S, Schalin-Jäntti C, Belaya Z, Gibb F, Lapauw B, Amrein K, Wicke C, Grasemann C, Krebs M, Ryhänen E, Makay Ö, Minisola S, Gaujlux S, Bertocchio JP, Hassan-Smith Z, Linglart A, Winter EM, Kollmann M, Zmierczak HG, Tsourdi E, Pilz S, Siggelkow H, Gittoes N, Marcocci C, Ka,enicky P, on behalf of the 2021 PARAT Working Group. European Journal of Endcrinology 2022;186:R33-R63
34. Okudan B, Seven B, Karci AC, Kilinckaya MF, Capraz M, Turhan T, Gülaldi NCM. Parathyroid Hormone on Osteoprotegerin Levels in Patients with Primary Hyperparathyroidism. Eurasian J Med 2022 Aug 11. https://doi.org/10.5152/eurasianjmed.2021.21197 Online ahead of print
35. Lenschow C, Wennmann A, Hendricks A, Germer C-T, Fassnacht M, Buck A, Werner RA, Plassmeier L, Schlegel N. Questionable value of [ 99mTc ]-sestamibi scintigraphy in patients with pHPT and negative ultrasound. Langenbecks Arch Surg 2022 Aug 9. https://doi.org/10.1007/s00423-022-02648-9 Online ahead of print
36. Axelsson KF, Wallander M, Johansson H, Harvey NC, Vandenput L, McCloskey E, Liu E, Kanis JA, Litsne H, Lorentzon M. Analysis of Comorbitities, Clinical Outcomes, and Parathyroidectomy in Adults With Primary Hyperparathyreoidism. JAMA Netw Open 2022;5:e2215396
37. Seib CD, Meng T , Suh I. Risk of Fracture Among Older Adults With Primary Hyperparathyroidism Receiving Parathyroidectomy vs Nonoperative Management. JAMA Intern Med 2022;182: 10-18
38. Osorio-Silla I, Gómez-Ramírez J, Valdazo-Gómez A, Fernández SS, García RP. What happens to the bone structure after normocalcemic primary hyperparathyroidism surgery? Surgery 2022;171:932-939
39. Victor F, Lemos ALP, de Holanda Ribas A, Bandeira L, Pimentel JH, de Andrade Damázio LO, Bandeira F. Occult Renal Calcifications in Patients with Normocalcemic Primary Hyperparathyroidism and Their Association with the Parathyroid Hormone-Vitamin D Axis. International Journal of Endocrinology 2022; Article ID 4558236, 6 pages https://doi.org/10.1155/2022/4558236
40. Kalaria T, Fenn J, Sanders A, Yates A, Duff C, Ashby H, Mohammed P, Ford C, Gama R. The Diagnosis of Normocalcaemic Hyperparathyroidism ist Strikingly Dissimilar Using Different Commercial Laboratory Assays. Horm Metab Res 2022;54:429-434
41. Choi HR, Choi SH, Hong N, Rhee Y, Kim JK, Lee CR, Kang S-W, Lee J, Jeong JJ, Nam KH, Chung WY. Comparisons between normocalcemic primary hyperparathyroidism and typical primary hyperparathyroidism. J Korean Med Sci 2022;37:e99 https://doi.org/10.3346/jkms.2022.37.e99
42. Acharya R, Kopczynska M, Goodmaker C, Mukherjee A, Doran H. Vitamin D repletion in primary hyperparathyroid patients undergoing parathyroidectomy leads to reduced symptomatic hypocalcaemia and reduced length of stay: a retrospective cohort study. Ann R Coll Surg Engl 2022;104:41-47
43. Lee JE, Hong N, Kim JK, Lee CR, Kang S-W, Jeong JJ, Nam K-H, Chung WY, Rhee Y. Analysis of the cause and management of persistent laboratory abnormalities occurring after the surgical treatment of primary hyperparathyroidism. Ann Surg Treat Res 2022;103:12-18
44. Kuchay MS, Mathew A, Kaur P, Mishra SK. Denosumab can be used successfully as a bridge to surgery in patients with severe hypercalcemia due to primary hyperparathyroidism. Arch Endocrinol Metab 2021;65:669-673
45. Roukain A, Alwan H, Bongiovanni M, Sykiotis GP, Kopp PA. Denosumab for the Treatment of Hypercalcemia in a Patient with Parathyreoid Carcinoma: A Case Report. Front. Endocrinol. 12:794988. https://doi.org/10.3389/fendo.2021.794988
46. Ryhänen EM, Koski AM, Löyttyniemi E, Välimäki MJ, Kiviniemi U, Schalin-Jäntti C. Postoperative zoledronic acid for osteoporosis in primary hyperparathyreoidism: a randomized placebo-controlled study. Eur J Endocrinol 2021;185:515-524
47. Enyi CO, D ́Souza B, Barloon L, Ilonze OJ, Chacko R. Relation of hyperparathyroidism and hypercalcemia to bipolar and psychotic disorders. PROC (BAYl UNIV MED CENT) 2022;35:540-542
48. Tanner CM, Cummings SR, Schwarzchild MA, Brown EG, Dorsey ER, Espay AJ, Galifianakis NB, Goldman SM, Litvan I, Luthra N, McFarland NR, Mitchell KT, Standaert DG, Bauer DC, Greenspan SL, Beck JC, Lyles KW. The TOPAZ study. A home-based trial of zolecronic acid t prevent fractures in neurodegenerative parkinsonism. Parkinson ́s Disease 2021; 7:16 ; https://doi.org/10.1038/s41531-021-00162-1
49. Li W, Ning Z, Yang Z, Fan T, Yao M, Zhang W, Wang M, Wen A, Wang J. Safety of denosumab versus zoledronic acid in the older adults with osteoporosis: a meta-analysis of cohort studies. Arch Osteoporos 2022;17: 84. https://doi.org/10.1007/s11657-022-01129-2
50. SØlling AS, HarslØf T, Langdahl B Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study. Journal of Bone and Mineral Research 2031; 36;1245-1254
51. Burckhardt P, Faouzi M, Buclin T, Lamy O, and the Swiss Denosumab Study Group (2021) Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases. Journal of Bone and Mineral Research 2021; 36: 1717-1728
52. Li M, Zhang Z, Xue Q, Li Q, Jin X, Dong J, Cheng Q, You L, Lin H, Tang H, Shen L, Gao X, Hu J, Chao A, Li P, Shi R, Zheng S, Zhang Y, Xiong X, Yu W, Xia W. Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study. Archives of Osteoporosis 2022;17:103
53. Liu ZM, Zhang M, Zong Y, Zhang D, Shen Z-B, Guan X-Q, Yin F. The efficiency and safety of alendronate versus teriparatide for treatment glucocorticoid-induced osteoporosis: A meta- analysis and systematic review of randomized controlled trials. PLoS ONE 17(5):e0267706. https://doi.org/10.1371/journal.pone.0267706
54. Chiba K, Okazaki N, Kurogi A, Watanabe T, Mori A, Suzuki N, Adachi K, Era M, Yokota K, Inoue T, Yabe Y, Furukawa K, Kondo C, Tsuda K, Ota S, Isobe Y, Miyazaki S, Morimoto S, Sato S, Nakashima S, Tashiro S, Yonekura A, Tomita M, Osaki M Randomized controlled trial of daily teriparatide, weekly high-dose teripartide, or bisphosphonate in patients with postmenopausal osteoporosis: The TERABIT study. Bone 2022;160:116416
55. Farlay D, Rizzo S, Dempster DW, Huang S, Chines A, Prown JP, Boivin G. Bone Mineral and Organic Properties in Postmenopausal Women Treated with Denosumab for Up to 10 years. Journal of Bone Mineral research 2022;37:856-864
56. Kendler DL, Cosman F, Stad RK, Ferrari S. Denosumab in the Treatment of Osteoporosis: 10 years later: a Narrative Review. Adv Ther 2022;39:58-74
57. Cosman F, Kendler D, Langdahl BL, Leder BZ, Lewiecki EM, Miyauchi A, Rojeski M, McDermott M, Oates MK, Milmont CE, Libanati C, Ferrari S. Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporosis International 2022;33:1243-1256
58. Tian A, Jia H, Zhu S, Lu B, Li Y, Ma J, Ma X. Romosozumab versus Teriparatide for the treatment of Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis through a Grade Analysis of Evidence. Orthopaedic Surgery 2021;13:1941-1950
59. Geusens P, Feldman R, Oates M, Thomas T, Makras P, Jakob F, Langdahl B, Wang Z, Rojeski M, Libanati C. Romosozumab reduces incidence of new vertebral fractures across severity grades among postmenopausal women with osteoporosis. Bone 2022;154: https://doi.org/10.1016/j.bone.2021.116209
60. Kobayakawa T, Miyazaki A, Takahashi J, Nakamura Y. Verification of efficacy and safety of ibandronate or denosumab for postmenopausal osteoporosis after 12-month treatment with romosozumab as sequential therapy: The prospective VICTOR study. Bone 2022;162: 116480. https://doi.org/10.1016/j.bone.2022.116480
61. Bislev LS, Laugesen-Grove D, Rejnmark L. Vitamin D and Muscle Health: A Systematic Review and Meta-analysis of Randomized Placebo-Controlled Trials. Journal of Bone and Mineral Research 2021; 36; 1651-1660
62. Waterhouse M, Sanguineti E, Baxter C, Romero BD, McLeod DSA, English DR, Armstrong BK, Ebeling PR, Hartel G, Kimlin MG, O ́Connell RL, Pham H, van der Pols JC, Venn AJ, Webb PM, Whiteman DC, Neale RE. Vitamin D supplementation and risk of falling: outcomes from the randomized, placebo-Controlled D-Health Trial. Journal of Cachexia, Sarcopenia and Muscle 2021;12:1428-1439
63. Dawson-Hughes B, Wang J, Barger K, Bischoff-Ferrari HA, Sempos CT, Durazo-Arvizu RA, Ceglia L. Intra-Trial Mean 25(OH)D and PTH Levels and Risk of Falling in Older Men and Women in the Boston STOP IT Trial. J Clin Endocrinol Metab 2022;107:e1932-e1937
64. Feng F, Shi G, Chen H, Jia P, Bao L, Xu F, Sun Q-C, Tang H. Comprehensive Interventions including Vitamin D Effectively Reduce the Risk of Falls in Elderly Osteoporotic Patients. Orthopaedic Surgery 2021;13:1262-1268
65. LeBoff MS, Chou SH, Ratliff KA, Cook NR, Khurana B, Kim E, Cawthon PM, Bauer DC, Black D, Gallagher JC, Lee IM, Buring JE, Manson JE. Supplemental Vitamin D and Incident Fractures in Midlife and Older Adults. N Engl J Med 2022;387:299-309
66. Zittermann A, Berthold HK, Pilz S. The effect of Vitamin D on fibroblast growth factor 23: a systematic review and meta-analysis of randomized controlled trials. Eur J Clin Nutr. 2022 Mar;76(3):488. https://doi.org/10.1038/s41430-021-01019-9

1. Osamura R.Y., Grossman A., Korbonits M., Kovacs K., Lopes M.B.S., Matsuno A., Trouillas J. WHO Classification of Tumours of Endocrine Organs. WHO; Lyon, France: 2017. Pituitary adenoma; pp. 14–18. Chapter 1: Tumors of the Pituitary Gland. ISBN: 978-92-832-4493-6.
2. Melmed S, Kaiser UB, Lopes MB, Bertherat J, Syro LV, Raverot G, Reincke M, Johannsson G, Beckers A, Fleseriu M, Giustina A, Wass JAH, Ho KKY. Clinical Biology of the Pituitary Adenoma.Endocr Rev. 2022 Apr 8:bnac010.
3. Deutschbein T, Jaursch-Hancke C, Knappe UJ, Saeger W, Flitsch J, Bojunga J, Buchfelder M, Ditzen B, Gerlach R, Gertzen E, Honegger J, Horstmann GA, Koch A, Kreitschmann- Andermahr I, Kunz M, Lagrèze WA, Nicolay NH, Paulus W, Reincke M, Schmidt MA, Weber mm, Wilhelm H, Fassnacht M. First German Guideline on Diagnostics and Therapy of Clinically Non-Functioning Pituitary Tumors. Exp Clin Endocrinol Diabetes. 2021 Mar;129(3):250-264. https://doi.org/10.1055/a-1373-4087
4. Han AJ, Varlamov EV, Fleseriu M. Nonfunctioning Pituitary Microadenomas: Should Imaging Interval be Extended? A Large Single-center Cohort Study. J Clin Endocrinol Metab. 2022 Feb 17;107(3):e1231-e1241. https://doi.org/10.1210/clinem/dgab748 PMID: 34648635.
5. Rubinstein G, Osswald A, Hoster E, Losa M, Elenkova A, Zacharieva S, Machado MC, Hanzu FA, Zopp S, Ritzel K, Riester A, Braun LT, Kreitschmann-Andermahr I, Storr HL, Bansal P, Barahona MJ, Cosaro E, Dogansen SC, Johnston PC, Santos de Oliveira R, Raftopoulos C, Scaroni C, Valassi E, van der Werff SJA, Schopohl J, Beuschlein F, Reincke M. Time to Diagnosis in Cushing's Syndrome: A Meta-Analysis Based on 5367 Patients. JCEM 2020. https://doi.org/10.1210/clinem/dgz136
6. Braun LT, Vogel F, Zopp S, Marchant Seiter T, Rubinstein G, Berr CM, Künzel H, Beuschlein F, Reincke M. Whom should we screen for Cushing's syndrome: The Endocrine Society Practice Guideline Recommendations 2008 revisited. J Clin Endocrinol Metab. 2022 Jun 22:dgac379. https://doi.org/10.1210/clinem/dgac379
7. Ebbehoj A, Søndergaard E, Jepsen P, Stochholm K, Svane HML, Madsen M, Poulsen PL, Jørgensen JOL The Socioeconomic Consequences of Cushing's Syndrome: A Nationwide Cohort Study. .J Clin Endocrinol Metab. 2022 Jun 16;107(7):e2921-e2929.
8. Gadelha M, Bex M, Feelders RA, Heaney AP, Auchus RJ, Gilis-Januszewska A, Witek P, Belaya Z, Yu Y, Liao Z, Ku CHC, Carvalho D, Roughton M, Wojna J, Pedroncelli AM, Snyder PJ Randomized Trial of Osilodrostat for the Treatment of Cushing Disease. .J Clin Endocrinol Metab. 2022 Jun 16;107(7):e2882-e2895. https://doi.org/10.1210/clinem/dgac178 PMID: 35325149 Free PMC article. Clinical Trial.
9. He X, Findling JW, Auchus RJ Glucocorticoid Withdrawal Syndrome following treatment of endogenous Cushing Syndrome. Pituitary. 2022 Jun;25(3):393-403. https://doi.org/10.1007/s11102-022-01218-y Epub 2022 Apr 26.
10. Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, Boguszewski CL, Bronstein MD, Buchfelder M, Carmichael JD, Casanueva FF, Castinetti F, Chanson P, Findling J, Gadelha M, Geer EB, Giustina A, Grossman A, Gurnell M, Ho K, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Kelly DF, Lacroix A, McCormack A, Melmed S, Molitch M, Mortini P, Newell-Price J, Nieman L, Pereira AM, Petersenn S, Pivonello R, Raff H, Reincke M, Salvatori R, Scaroni C, Shimon I, Stratakis CA, Swearingen B, Tabarin A, Takahashi Y, Theodoropoulou M, Tsagarakis S, Valassi E, Varlamov EV, Vila G, Wass J, Webb SM, Zatelli MC, Biller BMK. Consensus on diagnosis and management of Cushing's disease: a guideline update..Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-875. https://doi.org/10.1016/S2213-8587(21)00235-7 Epub 2021 Oct 20.PMID: 34687601 Free article. Review.
11. Esposito D, Ragnarsson O, Johannsson G, Olsson DS. Prolonged diagnostic delay in acromegaly is associated with increased morbidity and mortality. Eur J Endocrinol. 2020 Jun;182(6):523-531. https://doi.org/10.1530/EJE-20-0019 PMID: 32213651.
12. Carosi G, Mangone A, Sala E, Del Sindaco G, Mungari R, Cremaschi A, Ferrante E, Arosio M, Mantovani G Clinical and hormonal findings in patients presenting with high IGF-1 and growth hormone suppression after oral glucose load: a retrospective cohort study..Eur J Endocrinol. 2021 Jul 1;185(2):289-297. https://doi.org/10.1530/EJE-21-0024 PMID: 34081617 Free PMC article.
13. Hage M, Janot C, Salenave S, Chanson P , Kamenický P . MANAGEMENT OF ENDOCRINE DISEASE: Etiology and outcome of acromegaly in patients with a paradoxical GH response to glucose. Eur J Endocrinol. 2021 May 10;184(6):R261-R268. https://doi.org/10.1530/EJE-20-1448 PMID: 33830942 Review.
14. Atquet V, Alexopoulou O, Maiter D Characteristics and treatment responsiveness of patients with acromegaly and a paradoxical GH increase to oral glucose load.. Eur J Endocrinol. 2021 Jul 1;185(2):313-321. https://doi.org/10.1530/EJE-21-0324 PMID: 34085950.
15. Potorac I, Bonneville JF, Daly AF, de Herder W, Fainstein-Day P, Chanson P, Korbonits M, Cordido F, Baranski Lamback E, Abid M, Raverot V, Raverot G, Anda Apiñániz E, Caron P, Du Boullay H, Bildingmaier M, Bolanowski M, Laloi-Michelin M, Borson-Chazot F, Chabre O, Christin-Maitre S, Briet C, Diaz-Soto G, Bonneville F, Castinetti F, Gadelha MR, Oliveira Santana N, Stelmachowska-Banaś M, Gudbjartsson T, Villar-Taibo R, Zornitzki T, Tshibanda L, Petrossians P, Beckers A. Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases..J Clin Endocrinol Metab. 2022 Jul 14;107(8):e3313-e3320. https://doi.org/10.1210/clinem/dgac274
16. Coopmans EC, Postma MR, Wolters TLC, van Meyel SWF, Netea-Maier R, van Beek AP, Neggers SJCMM Predictors for Remission after Transsphenoidal Surgery in Acromegaly: A Dutch Multicenter Study.. J Clin Endocrinol Metab. 2021 May 13;106(6):1783-1792. https://doi.org/10.1210/clinem/dgab069
17. Sävendahl L, Polak M, Backeljauw P, Blair JC, Miller BS, Rohrer TR, Hokken-Koelega A, Pietropoli A, Kelepouris N, Ross J. Long-Term Safety of Growth Hormone Treatment in Childhood: Two Large Observational Studies: NordiNet IOS and ANSWER. J Clin Endocrinol Metab. 2021 May 13;106(6):1728-1741. https://doi.org/10.1210/clinem/dgab080
18. Johannsson G, Touraine P, Feldt-Rasmussen U, Pico A, Vila G, Mattsson AF, Carlsson M, Korbonits M, van Beek AP, Wajnrajch MP, Gomez R, Yuen KCJ. Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15 809 GH-Treated Patients. J Clin Endocrinol Metab. 2022 Jun 16;107(7):1906-1919. https://doi.org/10.1210/clinem/dgac199
19. Boguszewski MCS, Boguszewski CL, Chemaitilly W, Cohen LE, Gebauer J, Higham C, Hoffman AR, Polak M, Yuen KCJ, Alos N, Antal Z, Bidlingmaier M, Biller BMK, Brabant G, Choong CSY, Cianfarani S, Clayton PE, Coutant R, Cardoso-Demartini AA, Fernandez A, Grimberg A, Guðmundsson K, Guevara-Aguirre J, Ho KKY, Horikawa R, Isidori AM, Jørgensen JOL, Kamenicky P, Karavitaki N, Kopchick JJ, Lodish M, Luo X, McCormack AI, Meacham L, Melmed S, Mostoufi Moab S, Müller HL, Neggers SJCMM, Aguiar Oliveira MH, Ozono K, Pennisi PA, Popovic V, Radovick S, Savendahl L, Touraine P, van Santen HM, Johannsson G. Safety of growth hormone replacement in survivors of cancer and intracranial and pituitary tumours: a consensus statement. Eur J Endocrinol. 2022 Apr 21;186(6):P35-P52.
20. Laurer E, Sirovina A, Blaschitz A, Tischlinger K, Montero-Lopez R, Hörtenhuber T, Wimleitner M, Högler W The landscape of retesting in childhood-onset idiopathic growth hormone deficiency and its reversibility: a systematic review and meta-analysis. Eur J Endocrinol. 2022 Jun 29;187(2):265-278. https://doi.org/10.1530/EJE-21-1179 Print 2022 Aug 1.PMID: 35670597.
21. Zamanipoor Najafabadi AH, Zandbergen IM, de Vries F, Broersen LHA, van den Akker- van Marle ME, Pereira AM, Peul WC, Dekkers OM, van Furth WR, Biermasz NR Surgery as a Viable Alternative First-Line Treatment for Prolactinoma Patients. A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2020 Mar 1;105(3):e32-41.
22. Park JY, Choi W, Hong AR, Yoon JH, Kim HK, Jang WY, Jung S, Kang HC. Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas. Pituitary. 2021 Dec;24(6):955-963.
23. Baussart B, Villa C, Jouinot A, Raffin-Sanson ML, Foubert L, Cazabat L, Bernier M, Bonnet F, Dohan A, Bertherat J, Assié G, Gaillard S.Pituitary surgery as alternative to dopamine agonists treatment for microprolactinomas: a cohort study. Eur J Endocrinol. 2021 Oct 21;185(6):783-791.
24. Nordenström A, Ahmed SF, van den Akker E, Blair J, Bonomi M, Brachet C, Broersen LHA, Claahsen-van der Grinten HL, Dessens AB, Gawlik A, Gravholt CH, Juul A, Krausz C, Raivio T, Smyth A, Touraine P, Vitali D, Dekkers OM. Pubertal induction and transition to adult sex hormone replacement in patients with congenital pituitary or gonadal reproductive hormone deficiency: an Endo-ERN clinical practice guideline. Eur J Endocrinol. 2022 Apr 21;186(6):G9-G49. https://doi.org/10.1530/EJE-22-0073 PMID: 35353710 Free PMC article.
25. Fava D, Calandrino A, Calevo mg, Allegri AEM, Napoli F, Gastaldi R, Patti G, Casalini E, Bassi M, Accogli A, Al Yasin ARAA, Ramaglia A, Rossi A, Maghnie M, Morana G, Di Iorgi N.J Clinical, Endocrine and Neuroimaging Findings in Girls with Central Precocious Puberty. J Clin Endocrinol Metab. 2022 Jul 26:dgac422.
26. Maione L, Sarfati J, Gonfroy-Leymarie C, Salenave S, Brailly-Tabard S, Chanson P, Trabado S, Kaiser UB, Young J.J Reproductive Phenotypes in Men With Acquired or Congenital Hypogonadotropic Hypogonadism: A Comparative Study. Clin Endocrinol Metab. 2022 Jun 16;107(7):e2812-e2824. https://doi.org/10.1210/clinem/dgac194
27. Shah R, Patil V, Sarathi V, Lila AR, Zacharin M, Krishnappa B, Sehemby M, Jaiswal SK, Jadhav PL, Ramteke-Jadhav S, Shah N, Bandgar T. Prior testosterone replacement therapy may impact spermatogenic response to combined gonadotropin therapy in severe congenital hypogonadotropic hypogonadism. Pituitary. 2021 Jun;24(3):326- 333. https://doi.org/10.1007/s11102-020-01111-6
28. Castle-Kirszbaum M, Fuller P, Wang YY, King J, Goldschlager T. Diabetes insipidus after endoscopic transsphenoidal surgery: multicenter experience and development of the SALT score. Pituitary. 2021 Dec;24(6):867-877. https://doi.org/10.1007/s11102-021-01159-y Epub 2021 May 26.
29. Muller I, Cannavaro D, Dazzi D, Covelli D, Mantovani G, Muscatello A, Ferrante E, Orsi E, Resi V, Longari V, Cuzzocrea M, Bandera A, Lazzaroni E, Dolci A, Ceriotti F, Re TE, Gori A, Arosio M, Salvi M. SARS-CoV-2-related atypical thyroiditis. Lancet Diabetes Endocrinol. 2020 Sep;8(9):739-741.
30. Lui DTW, Lee CH, Cheung CYY, Mak JHC, Fong CHY, Lui BWC, Cheung VSY, Chow WS, Lee ACH, Tam AR, Pang P, Ho TY, Tan KCB, Woo YC, Hung IFN, Lam KSL. Effect of COVID- 19 Vaccines on Thyroid Function and Autoimmunity and Effect of Thyroid Autoimmunity on Antibody Response. J Clin Endocrinol Metab. 2022 Aug 18;107(9):e3781-e3789.
31. Oğuz SH, Şendur SN, İremli BG, Gürlek A, Erbas T, Ünlütürk U. SARS-CoV-2 Vaccine- induced Thyroiditis: Safety of Revaccinations and Clinical Follow-up. J Clin Endocrinol Metab. 2022 Apr 19;107(5):e1823-e1834.
32. Chee YJ, Liew H, Hoi WH, Lee Y, Lim B, Chin HX, Lai RTR, Koh Y, Tham M, Seow CJ, Quek ZH, Chen AW, Quek TPL, Tan AWK, Dalan R. SARS-CoV-2 mRNA Vaccination and Graves' Disease: A Report of 12 Cases and Review of the Literature. J Clin Endocrinol Metab. 2022 May 17;107(6):e2324-e2330.
33. Korevaar TIM. Euthyroid Thyroperoxidase Antibody Positivity during Pregnancy, to Treat or Not to Treat? Endocrinol Metab (Seoul). 2022 Jun;37(3):387-391.
34. van Dijk MM, Vissenberg R, Fliers E, van der Post JAM, van der Hoorn MP, de Weerd S, Kuchenbecker WK, Hoek A, Sikkema JM, Verhoeve HR, Broeze KA, de Koning CH, Verpoest W, Christiansen OB, Koks C, de Bruin JP, Papatsonis DNM, Torrance H, van Wely M, Bisschop PH, Goddijn M. Levothyroxine in euthyroid thyroid peroxidase antibody positive women with recurrent pregnancy loss (T4LIFE trial): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2022 May;10(5):322-329.
35. Dhillon-Smith RK, Middleton LJ, Sunner KK, Cheed V, Baker K, Farrell-Carver S, et al. Levothyroxine in women with thyroid peroxidase antibodies before conception. N Engl J Med 2019;380:1316-25.
36. Wang H, Gao H, Chi H, Zeng L, Xiao W, Wang Y, et al. Effect of levothyroxine on miscarriage among women with normal thyroid function and thyroid autoimmunity undergoing in vitro fertilization and embryo transfer: a randomized clinical trial. JAMA 2017;318:2190-8.
37. Korevaar TIM, Dhillon-Smith R. Levothyroxine treatment in euthyroid women positive for thyroid peroxidase antibodies and recurrent pregnancy loss. Lancet Diabetes Endocrinol. 2022 May;10(5):299-301.
38. Toloza FJK, Derakhshan A, Männistö T, Bliddal S, Popova PV, Carty DM, Chen L, Taylor P, Mosso L, Oken E, Suvanto E, Itoh S, Kishi R, Bassols J, Auvinen J, López-Bermejo A, Brown SJ, Boucai L, Hisada A, Yoshinaga J, Shilova E, Grineva EN, Vrijkotte TGM, Sunyer J, Jiménez-Zabala A, Riaño-Galan I, Lopez-Espinosa MJ, Prokop LJ, Singh Ospina N, Brito JP, Rodriguez-Gutierrez R, Alexander EK, Chaker L, Pearce EN, Peeters RP, Feldt-Rasmussen U, Guxens M, Chatzi L, Delles C, Roeters van Lennep JE, Pop VJM, Lu X, Walsh JP, Nelson SM, Korevaar TIM, Maraka S. Association between maternal thyroid function and risk of gestational hypertension and pre-eclampsia: a systematic review and individual-participant data meta-analysis. Lancet Diabetes Endocrinol. 2022 Apr;10(4):243-252.
39. Vermiglio F, Moleti M. From preeclampsia to thyroid dysfunction: a long and winding road. Lancet Diabetes Endocrinol. 2022 Apr;10(4):232-233.
40. Alexander EK, Pearce EN, Brent GA, Brown RS, Chen H, Dosiou C, Grobman WA, Laurberg P, Lazarus JH, Mandel SJ, Peeters RP, Sullivan S. 2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum. Thyroid. 2017 Mar;27(3):315-389.

1. Bartalena L, Kahaly GJ, Baldeschi L, Dayan CM, Eckstein A, Marcocci C, Marinò M, Vaidya B, Wiersinga WM; EUGOGO †. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021 Aug 27;185(4):G43-G67.
2. Girnita L, Smith TJ, Janssen JAMJL. It takes two to Tango: IGF-I and TSH Receptors in Thyroid Eye Disease. J Clin Endocrinol Metab. 2022 Feb 15;107(Suppl 1):S1-S12.
3. Fernando R, Caldera O, Smith TJ. Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy. Proc Natl Acad Sci U S A. 2021 Dec 28;118(52):e2114244118.
4. Ugradar S, Kossler AL, Douglas R, Cockerham K. A Paradigm Shift in the Management of Thyroid Eye Disease How Teprotumumab Has Changed the Therapeutic Interface. J Neuroophthalmol. 2022 Mar 1;42(1):26-34.
5. Douglas RS, Kossler AL, Abrams J, Briceño CA, Gay D, Harrison A, Lee M, Nguyen J, Joseph SS, Schlachter D, Tan J, Lynch J, Oliver L, Perry R, Ugradar S. Expert Consensus on the Use of Teprotumumab for the Management of Thyroid Eye Disease Using a Modified-Delphi Approach. Neuroophthalmol. 2022 Mar 24;42(3):334-9.
6. Kossler AL, Douglas R, Dosiou C. Teprotumumab and the Evolving Therapeutic Landscape in Thyroid Eye Disease. J Clin Endocrinol Metab. 2022 Sep., S36–S46. https://doi.org/10.1210/clinem/dgac168
7. Kahaly GJ, Douglas RS, Holt RJ, Sile S, Smith TJ. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials. Lancet Diabetes Endocrinol. 2021 Jun;9(6):360-372.
8. Sears CM, Azad AD, Amarikwa L, Pham BH, Men CJ, Kaplan DN, Liu J, Hoffman AR, Swanson A, Alyono J, Lee JY, Dosiou C, Kossler AL. Hearing Dysfunction After Treatment With Teprotumumab for Thyroid Eye Disease. Am J Ophthalmol. 2022 Aug;240:1-13.
9. Bednarczuk T, Pearce SH. The knowns and unknowns of teprotumumab for thyroid eye disease. Lancet Diabetes Endocrinol. 2021 Jun;9(6):323-325.
10. Strawbridge JC, Meer EA, Singh P, Rootman DB Google Searches for Thyroid Eye Disease After Regulatory Approval of Teprotumumab. JAMA Ophthalmol 2022 Jun 1;140(6):639-642.
11. Barbesino G, Salvi M, Freitag SK. Future Projections in Thyroid Eye Disease. J Clin Endocrinol Metab. 2022 Sep., S47–S56. https://doi.org/10.1210/clinem/dgac252
12. Evron JM, Hummel SL, Reyes-Gastelum D, Haymart MR, Banerjee M, Papaleontiou M. Association of Thyroid Hormone Treatment Intensity With Cardiovascular Mortality Among US Veterans. JAMA Netw Open. 2022 May 2;5(5):e2211863.
13. Vardarli I, Brandenburg T, Hegedüs L, Attanasio R, Nagy E, Papini E, Perros P, Weidemann F, Herrmann K, Führer D. A Questionnaire Survey of German Thyroidologists on the Use of Thyroid Hormones in Hypothyroid and Euthyroid Patients: The THESIS (Treatment of Hypothyroidism in Europe by Specialists: An International Survey) Collaborative. Exp Clin Endocrinol Diabetes. 2022 May 31. https://doi.org/10.1055/a-1832-0644
14. Janett-Pellegri C, Wildisen L, Feller M, Del Giovane C, Moutzouri E, Grolimund O, Walter P, Waeber G, Marques-Vidal P, Vollenweider P, Rodondi N. Prevalence and factors associated with chronic use of levothyroxine: A cohort study. PLoS One. 2021 Dec 20;16(12):e0261160.
15. Hegedüs L, Bianco AC, Jonklaas J, Pearce SH, Weetman AP, Perros P. Primary hypothyroidism and quality of life. Nat Rev Endocrinol. 2022 Apr;18(4):230-242.
16. Shakir MKM, Brooks DI, McAninch EA, Fonseca TL, Mai VQ, Bianco AC, Hoang TD.J Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism. Clin Endocrinol Metab. 2021 Oct 21;106(11):e4400-e4413.
17. Bonnema SJ, Riis KR, Jensen CZ, Thvilum M, Nygaard B. Letter to the Editor From S.J.Bonnemaet al: "Comparative Effectiveness of Levothyroxine, Desiccated Thyroid Extract, and Levothyroxine+Liothyronine in Hypothyroidism". J Clin Endocrinol Metab. 2022 Feb 17;107(3):e1317-e1318.
18. Chaker L, Razvi S, Bensenor IM, Azizi F, Pearce EN, Peeters RP. Hypothyroidism. Nat Rev Dis Primers. 2022 May 19;8(1):30. https://doi.org/10.1038/s41572-022-00357-7
19. Salvatore D, Porcelli T, Ettleson MD, Bianco AC. The relevance of T3 in the management of hypothyroidism. Lancet Diabetes Endocrinol. 2022 May;10(5):366-372.
20. Sterenborg RBTM, Galesloot TE, Teumer A, Netea-Maier RT, Speed D, Meima ME, Visser WE, Smit JWA, Peeters RP, Medici M. The Effects of Common Genetic Variation in 96 Genes Involved in Thyroid Hormone Regulation on TSH and FT4 Concentrations. J Clin Endocrinol Metab. 2022 May 17;107(6):e2276-e2283.
21. Ettleson MD, Bianco AC, Wan W, Laiteerapong N. Suboptimal Thyroid Hormone Replacement Is Associated With Worse Hospital Outcomes. J Clin Endocrinol Metab. 2022 Jul 14;107(8):e3411-e3419.
22. Yang J, Zheng Y, Li C, Liu Y, Zhou Q, Gao J, Meng X, Zhang K, Wang W, Shao C, Tang YD. The Impact of Subclinical Hyperthyroidism on Cardiovascular Prognosis in Patients Undergoing Percutaneous Coronary Intervention. J Clin Endocrinol Metab. 2022 Mar 24;107(4):986-997.
23. Mehran L, Delbari N, Amouzegar A, Hasheminia M, Tohidi M, Azizi F. Reduced Sensitivity to Thyroid Hormone Is Associated with Diabetes and Hypertension. J Clin Endocrinol Metab. 2022 Jan 1;107(1):167-176.
24. Laclaustra M, Moreno-Franco B, Lou-Bonafonte JM, Mateo-Gallego R, Casasnovas JA, Guallar-Castillon P, Cenarro A, Civeira F. Impaired Sensitivity to Thyroid Hormones Is Associated With Diabetes and Metabolic Syndrome. Diabetes Care. 2019 Feb;42(2):303- 310.
25. van Vliet NA, van Heemst D, Almeida OP, Åsvold BO, Aubert CE, Bae JB, Barnes LE, Bauer DC, Blauw GJ, Brayne C, Cappola AR, Ceresini G, Comijs HC, Dartigues JF, Degryse JM, Dullaart RPF, van Eersel MEA, den Elzen WPJ, Ferrucci L, Fink HA, Flicker L, Grabe HJ, Han JW, Helmer C, Huisman M, Ikram MA, Imaizumi M, de Jongh RT, Jukema JW, Kim KW, Kuller LH, Lopez OL, Mooijaart SP, Moon JH, Moutzouri E, Nauck M, Parle J, Peeters RP, Samuels MH, Schmidt CO, Schminke U, Slagboom PE, Stordal E, Vaes B, Völzke H, Westendorp RGJ, Yamada M, Yeap BB, Rodondi N, Gussekloo J, Trompet S; Thyroid Studies Collaboration. Association of Thyroid Dysfunction With Cognitive Function: An Individual Participant Data Analysis. JAMA Intern Med. 2021 Nov 1;181(11):1440-1450.
26. Wildisen L, Feller M, Del Giovane C, Moutzouri E, Du Puy RS, Mooijaart SP, Collet TH, Poortvliet RKE, Kearney P, Quinn TJ, Klöppel S, Bauer DC, Peeters RP, Westendorp R, Aujesky D, Gussekloo J, Rodondi N. Effect of Levothyroxine Therapy on the Development of Depressive Symptoms in Older Adults With Subclinical Hypothyroidism: An Ancillary Study of a Randomized Clinical Trial. JAMA Netw Open. 2021 Feb 1;4(2):e2036645.
27. Biondi B, Cappola AR. Subclinical hypothyroidism in older individuals. Lancet Diabetes Endocrinol. 2022 Feb;10(2):129-141.
28. Meling Stokland AE, Ueland G, Lima K, Grønning K, Finnes TE, Svendsen M, Ewa Tomkowicz A, Emblem Holte S, Therese Sollid S, Debowska A, Singsås H, Landsverk Rensvik M, Lejon H, Sørmo DE, Svare A, Blika S, Milova P, Korsgaard E, Husby Ø, Breivik L, Jørgensen AP, Sverre Husebye E. Autoimmune Thyroid Disorders in Autoimmune Addison Disease. J Clin Endocrinol Metab. 2022 May 17;107(6):e2331-e2338.
29. Muir CA, Clifton-Bligh RJ, Long GV, Scolyer RA, Lo SN, Carlino MS, Tsang VHM, Menzies AM. Thyroid Immune-related Adverse Events Following Immune Checkpoint Inhibitor Treatment. J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3704-e3713.
30. Kotwal A, Kottschade L, Ryder M. PD-L1 Inhibitor-Induced Thyroiditis Is Associated with Better Overall Survival in Cancer Patients. Thyroid. 2020 Feb;30(2):177-184.
31. Iwama S, Kobayashi T, Yasuda Y, Okuji T, Ito M, Ando M, Zhou X, Yamagami A, Onoue T, Kawaguchi Y, Miyata T, Sugiyama M, Takagi H, Hagiwara D, Suga H, Banno R, Hase T, Morise M, Wakahara K, Yokota K, Kato M, Nishio N, Tanaka C, Miyata K, Ogura A, Ito T, Sawada T, Shimokata T, Niimi K, Ohka F, Ishigami M, Gotoh M, Hashimoto N, Saito R, Kiyoi H, Kajiyama H, Ando Y, Hibi H, Sone M, Akiyama M, Kodera Y, Arima H. Increased Risk of Thyroid Dysfunction by PD-1 and CTLA-4 Blockade in Patients Without Thyroid Autoantibodies at Baseline. J Clin Endocrinol Metab. 2022 Mar 24;107(4):e1620-e1630.
32. Muir CA, Wood CCG, Clifton-Bligh RJ, Long GV, Scolyer RA, Carlino MS, Menzies AM, Tsang VHM. Association of Antithyroid Antibodies in Checkpoint Inhibitor-Associated Thyroid Immune-Related Adverse Events. J Clin Endocrinol Metab. 2022 Apr 19;107(5):e1843- e1849.
33. Kobayashi T, Iwama S, Yamagami A, Yasuda Y, Okuji T, Ito M, Zhou X, Ando M, Onoue T, Miyata T, Sugiyama M, Hagiwara D, Suga H, Banno R, Hase T, Morise M, Ito T, Kikumori T, Inoue M, Ando Y, Masuda N, Kawashima H, Hashimoto N, Arima H. Elevated TSH level, TgAb and prior use of ramucirumab or TKIs as risk factors for thyroid dysfunction in PD-L1 blockade. J Clin Endocrinol Metab. 2022 Aug 3:dgac467. https://doi.org/10.1210/clinem/dgac467
34. Ippolito S, Gallo D, Rossini A, Patera B, Lanzo N, Fazzino GFM, Piantanida E, Tanda ML. SARS-CoV-2 vaccine-associated subacute thyroiditis: insights from a systematic review. J Endocrinol Invest. 2022 Jun;45(6):1189-1200.

Prophylaxe, Diagnostik und Therapie der OSTEOPOROSE bei postmenopausalen Frauen und Männern (DVO, 2017, Retrieved from https://www.dv-osteologie.org/uploads/Leitlinie 2017/Finale Version Leitlinie Osteoporose 2017_end.pdf)
Geschlechtsinkongruenz, Geschlechtsdysphorie und Trans-Gesundheit: S3-Leitlinie zur Diagnostik, Beratung und Behandlung (AWMF, n.d., https://doi.org/10.2018/Version)
S2k-Leitlinie Neuroendokrine Tumore (Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) et al., 2018, https://doi.org/10.1055/a-0604-2924)
Nicht alkoholische Fettlebererkrankungen (Roeb et al., 2015, https://doi.org/10.1055/s-0035-1553193)
S1-Leitlinie Gynäkomastie im Erwachsenenalter (Schanz et al., n.d., Retrieved from https://www.awmf.org/uploads/tx_szleitlinien/013-039l_S1_Gynaekomastie_Erwachsene_2016-05.pdf)
Operative Therapie benigner Schilddrüsenerkrankungen (Retrieved from https://www.awmf.org/uploads/tx_szleitlinien/088-007l_S2k_operative_Therapie_benigner_Schilddrüsenerkrankungen_2015-10.pdf)
S2k-Leitlinie Operative Therapie von Nebennierentumoren (Retrieved from https://www.awmf.org/uploads/tx_szleitlinien/088-008l_S2k_Operative-Therapie_Nebennierentumoren_2018-11.pdf)
Erhöhter TSH-Wert in der Hausarztpraxis (Retrieved from https://www.awmf.org/uploads/tx_szleitlinien/053-046l_S2k_erhoehter_TSH_Wert_2017-04.pdf)
S3-Leitlinie Antiresorptiva-assoziierte Kiefernekrosen (AR-ONJ) (Schiegnitz et al., n.d., Retrieved from https://www.awmf.org/uploads/tx_szleitlinien/007-091l_S3_Antiresorptiva-assoziierte-Kiefernekrosen-AR-ONJ_2018-12.pdf)

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) (Davies et al., 2018, https://doi.org/10.2337/dci18-0033)
2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol.(Grundy et al., 2018, https://doi.org/10.1161/CIR.0000000000000625)
Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome (Teede et al., 2018, https://doi.org/10.1093/humrep/dey256)
ESHRE Guideline: management of women with premature ovarian insufficiency.(European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI et al., 2016, https://doi.org/10.1093/humrep/dew027)
Management of adrenal incidentalomas: European Society of Endocrinology Clinical Practice Guideline in collaboration with the European Network for the Study of Adrenal Tumors. (Fassnacht et al., 2016, https://doi.org/10.1530/EJE-16-0467)
European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors(Fassnacht et al., 2018, https://doi.org/10.1530/EJE-18-0608)
European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma (Plouin et al., 2016, https://doi.org/10.1530/EJE-16-0033)
Consensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiency.(Husebye et al., 2014, https://doi.org/10.1111/joim.12162)
European Society of Endocrine Surgeons (ESES) and European Network for the Study of Adrenal Tumours (ENSAT) recommendations for the surgical management of adrenocortical carcinoma (Gaujoux & Mihai, 2017, https://doi.org/10.1002/bjs.10414)
European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas (Raverot et al., 2018, https://doi.org/10.1530/EJE-17-0796)
Clinical practice guidelines for the care of girls and women with Turner syndrome: proceedings from the 2016 Cincinnati International Turner Syndrome Meeting.(Gravholt et al., 2017, https://doi.org/10.1530/EJE-17-0430)
European Society of Endocrinology Clinical Guideline: Treatment of chronic hypoparathyroidism in adults.(Bollerslev et al., 2015, https://doi.org/10.1530/EJE-15-0628)
Clinical practice guideline on diagnosis and treatment of hyponatraemia (Spasovski et al., 2014, https://doi.org/10.1530/EJE-13-1020)

https://www.eurothyroid.com/guidelines/eta_guidelines.html
2018 European Thyroid Association (ETA) Guidelines on the Diagnosis and Management of Central Hypothyroidism.(Persani et al., 2018, https://doi.org/10.1159/000491388)
2018 European Thyroid Association Guideline for the Management of Graves' Hyperthyroidism.(Kahaly et al., 2018, https://doi.org/10.1159/000490384)
2018 European Thyroid Association (ETA) Guidelines for the Management of Amiodarone-Associated Thyroid Dysfunction.(Bartalena et al., 2018, https://doi.org/10.1159/000486957)
European Thyroid Association Guidelines for Ultrasound Malignancy Risk Stratification of Thyroid Nodules in Adults: The EU-TIRADS.(Russ et al., 2017, https://doi.org/10.1159/000478927)
The 2015 European Thyroid Association Guidelines on Diagnosis and Treatment of Endogenous Subclinical Hyperthyroidism (Biondi et al., 2015, https://doi.org/10.1159/000438750)
The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.(Bartalena et al., 2016, https://doi.org/10.1159/000443828)
2013 European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer.(Leenhardt et al., 2013, https://doi.org/10.1159/000354537)

https://www.thyroid.org/professionals/ata-professional-guidelines
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer (Haugen et al., 2015, https://doi.org/10.1089/thy.2015.0020)
2017 Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and the Postpartum (Alexander et al., 2017, https://doi.org/10.1089/thy.2016.0457)
2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (Ross et al., 2016, https://doi.org/10.1089/thy.2016.0229)
Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma (Wells et al., 2015, https://doi.org/10.1089/thy.2014.0335)
Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement (Jonklaas et al., 2014, https://doi.org/10.1089/thy.2014.0028)
American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer (Smallridge et al., 2012, https://doi.org/10.1089/thy.2012.0302)

https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines

Adrenal

Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency | 2018: https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/primary-aldosteronism
The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment | 2016: https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/primary-aldosteronism
Diagnosis and Treatment of Primary Adrenal Insufficiency | 2016: https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/primary-adrenal-insufficiency
Treatment of Cushing’s Syndrome | 2015: https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/treatment-of-cushing-syndrome
Diagnosis and Treatment of Pheochromocytoma and Paraganglioma | 2014 https://doi.org/10.1210/jc.2014-1498
Diagnosis of Cushing's Syndrome | 2008 https://doi.org/10.1210/jc.2008-0125

Bone Health and Osteoporosis

Paget's Disease of Bone | 2014 https://doi.org/10.1210/jc.2014-2910
Osteoporosis in Men | 2012 https://doi.org/10.1210/jc.2011-3045
Evaluation, Treatment, and Prevention of Vitamin D Deficiency | 2011 https://doi.org/10.1210/jc.2011-0385

Cardiovascular Endocrinology

The Management of Primary Aldosteronism: Case Detection, Diagnosis, and Treatment | 2016 https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/primary-aldosteronism
Evaluation and Treatment of Hypertriglyceridemia | 2012 https://doi.org/10.1210/jc.2011-3213

Glucose Metabolism

Evaluation and Management of Adult Hypoglycemic Disorders | 2009 https://doi.org/10.1210/jc.2008-1410

Endocrine Neoplasia and Cancer

Hypothalamic–Pituitary and Growth Disorders in Survivors of Childhood Cancer | 2018 https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/disorders-in-survivors-of-childhood-cancer

Female Reproductive Endocrinology

Evaluation and Treatment of Hirsutism in Premenopausal Women | 2018 https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/hirsutism
Functional Hypothalamic Amenorrhea | 2017 https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/hypothalamic-amenorrhea
Treatment of Symptoms of the Menopause | 2015 https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/treatment-of-menopause

Male Reproductive Endocrinology

Testosterone Therapy in Men with Hypogonadism ǀ 2018 https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/testosterone-therapy

Neuroendocrinology

Hormonal Replacement in Hypopituitarism in Adults | 2016 https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/hormone-replacement-in-hypopituitarism
Acromegaly | 2014 https://doi.org/10.1210/jc.2014-2700
Diagnosis and Treatment of Hyperprolactinemia | 2011 https://doi.org/10.1210/jc.2010-1692
Evaluation and Treatment of Adult Growth Hormone Deficiency | 2011 https://doi.org/10.1210/jc.2011-0179
Pituitary Incidentaloma | 2011 https://doi.org/10.1210/jc.2010-1048

Transgender Medicine

Endocrine Treatment of Gender-Dysphoric/Gender-Incongruent Persons | 2017 https://www.endocrine.org/guidelines-and-clinical-practice/clinical-practice-guidelines/gender-dysphoria-gender-incongruence